US 10,111,953 B2Grant

Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)

Issue Date:2018-10-30

•12 Claims

•13 Drawing Sheets

Abstract

The present invention provides methods for reducing various lipoprotein fractions in the serum of patients. The methods of the invention include reducing serum remnant cholesterol, and/or the serum concentration of one or more LDL-C subfractions in a patient. The methods of the present invention comprise selecting a patient who exhibits elevated serum lipoproteins, and administering to the patient a pharmaceutical composition comprising a PCSK9 inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody such as the exemplary antibody referred to herein as mAb316P.

Metadata

Assignee

Regeneron Pharmaceuticals, Inc.

Inventors

Gary Swergold
William J. Sasiela
Robert C. Pordy

Application Information

Application Number:US 14/290,544

Filing Date:2014-05-29

Priority Date:2013-05-30

Art Unit:1644

Classifications

IPC:

A61K39/395C07K16/40A61K31/40A61K39/00

Patent Drawings (13 sheets)

Description

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit under 35 U.S.C. § 119(e) of U.S. provisional application Nos. 61/828,753, filed on May 30, 2013; 61/901,705, filed on Nov. 8, 2013; 61/919,836, filed on Dec. 23, 2013; 61/935,358, filed on Feb. 4, 2014; 61/953,959, filed on Mar. 17, 2014; and 61/991,738, filed on May 12, 2014, the disclosures of which are herein incorporated by reference in their entireties.

FIELD OF THE INVENTION

[0002] The present invention relates to the field of therapeutic treatments of diseases and disorders which are associated with elevated levels of lipoproteins. More specifically, the invention relates to the administration of PCSK9 inhibitors to reduce the levels of serum remnant cholesterol and other lipoprotein subfractions in a patient.

BACKGROUND

[0003] Remnant cholesterol (also referred to as remnant lipoprotein) is a category of cholesterol that comprises non-HDL and non-LDL cholesterol. Remnant lipoproteins are products of VLDL lipolysis, and include VLDL₃and intermediate-density lipoproteins (IDL, the direct precursor to LDL formation). Serum remnant cholesterol level has been identified as a predictive risk factor for coronary artery disease. In addition to remnant cholesterol, there are several subfractions of low density lipoprotein cholesterol (LDL-C) that may have relevance with regard to cardiovascular health. In particular, LDL-C is composed of a continuum of LDL particles of different densities and states of lipidation. Therapeutic reduction of serum remnant cholesterol and other lipoprotein subfraction levels may be a means for treating or reducing the risk of cardiovascular disorders.

[0004] PCSK9 is a proprotein convertase belonging to the proteinase K subfamily of the secretory subtilase family. The use of PCSK9 inhibitors (anti-PCSK9 antibodies) to reduce serum total cholesterol, LDL cholesterol and serum triglycerides is described in U.S. Pat. Nos. 8,062,640, 8,357,371, and US Patent Application Publication No. 2013/0064834.

BRIEF SUMMARY OF THE INVENTION

[0005] The present invention provides methods for reducing various lipoproteins and lipoprotein fractions in the serum of a patient. The patient can be a patient with hypercholesterolemia or at risk of developing hypercholesterolemia, or who has or is at risk of developing a cardiovascular disease.

[0006] The methods of the present invention comprise selecting a patient with an elevated serum level of a particular lipoprotein or lipoprotein fraction, and administering to the patient a pharmaceutical composition comprising an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9). According to certain aspects of the invention, the patient is selected on the basis of having an elevated serum remnant cholesterol level. According to certain other aspects of the invention, the patient is selected on the basis of having an elevated serum very low-density lipoprotein cholesterol level (e.g., elevated serum VLDL-C, VLDL₁-C, VLDL₂-C, VLDL₁₊₂-C, VLDL₃-C, etc.). According to yet other aspects of the invention, the patient is selected on the basis of having an elevated serum intermediate-density lipoprotein cholesterol (IDL-C) level. According to certain other aspects of the invention, the patient is selected on the basis of having an elevated serum level of one or more low-density lipoprotein cholesterol (LDL-C) subfraction (e.g., elevated serum LDL₁-C, LDL₂-C, LDL₃-C, LDL₄-C, LDL₃₊₄-C, etc.). According to certain aspects of the present invention, the patient is additionally or alternatively selected on the basis of having an elevated serum level of Lp(a).

[0007] The patient may also be selected on the basis of exhibiting additional risk factors for such diseases and disorders in which a reduction in lipoprotein levels would be beneficial or risk-lowering. For example, patients with hypercholesterolemia (e.g., heFH, nonFH, etc.) may be good candidates for treatment with the therapeutic methods of the present invention.

[0008] PCSK9 inhibitors which may be administered in accordance with the methods of the present invention include, e.g., anti-PCSK9 antibodies or antigen-binding fragments thereof. Specific exemplary anti-PCSK9 antibodies which may be used in the practice of the methods of the present invention include any antibodies or antigen-binding fragments as set forth in U.S. Pat. No. 8,062,640, and/or disclosed herein.

[0009] The PCSK9 inhibitor may be administered to a subject subcutaneously or intravenously. Furthermore, the PCSK9 inhibitor may be administered to a patient who is on a therapeutic statin regimen at the time of therapeutic intervention.

[0010] Other embodiments of the present invention will become apparent from a review of the ensuing detailed description.

BRIEF DESCRIPTION OF THE FIGURES

[0011] FIG. 1 shows the dynamic relationship between mAb316P, free (unbound) PCSK9, and LDL-C levels following a single dose of mAb316P 150 mg SC in health subjects who were not receiving background statin therapy.

[0012] FIG. 2 shows the mean concentration of free mAb316P in HeFH and non-FH patients receiving mAb316P 50, 100, or 150 mg SC plus atorvastatin or mAb316P 150 mg SC plus diet only. Dotted line indicates quantitation limit for free PCSK9 (0.0312 mg/dL)

[0013] FIG. 3 shows the mean percentage change in LDL-C from baseline versus mean total mAb316P concentration (mg/dL) in patients (HeFH and non-FH combined; n−21 receiving mAb316P 150 mg SC on Study Days 1, 29, and 43. Points indicate sampling times; h, hour; d, day. The hysteresis curve moves in a clockwise direction over time, as indicated by the arrows, demonstrating the temporal relationship between mAb316P concentration and change in LDL-C.

[0014] FIG. 4 shows mean baseline free PCSK9 levels in non-FH patients receiving atorvastatin or diet alone (no statin).

[0015] FIG. 5 shows LDL-C efficacy curves for patients receiving mAb316P 150 mg SC or placebo±atorvastatin.

[0016] FIG. 6 shows the mean percentage change in LDL-C from baseline over time in hypercholesterolemic patients on concomitant statin therapy following administration of mAb316P 50 mg, 100 mg, or 150 mg Q2W, 200 mg or 300 mg Q4W, or placebo. Delta symbol (Δ) corresponds to LOCF means.

[0017] FIGS. 7-9 show the mean (SD) levels of cholesterol in VLDL and serum remnant lipoprotein subfractions and triglycerides before and after treatment for placebo and mAb316P 150 mg Q2W in three different clinical studies (A, B, and C, as summarized in Table 1 herein). FIG. 7 depicts the results for Study A, FIG. 8 depicts the results for Study B, and FIG. 9 depicts the results for Study C.

[0018] FIGS. 10-12 show the mean (SD) levels of cholesterol in LDL subfractions before and after treatment for placebo and mAb316P 150 mg Q2W in three different clinical studies (A, B, and C, as summarized in Table 1 herein). FIG. 10 depicts the results for Study A, FIG. 11 depicts the results for Study B, and FIG. 12 depicts the results for Study C.

[0019] FIG. 13, panels A and B, show the dose response changes in apo CII and apo CIII, respectively, for all doses in Study A (as summarized in Table 1 herein).

DETAILED DESCRIPTION

[0020] Before the present invention is described, it is to be understood that this invention is not limited to particular methods and experimental conditions described, as such methods and conditions may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims.

[0021] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. As used herein, the term “about,” when used in reference to a particular recited numerical value, means that the value may vary from the recited value by no more than 1%. For example, as used herein, the expression “about 100” includes 99 and 101 and all values in between (e.g., 99.1, 99.2, 99.3, 99.4, etc.).

[0022] Although any methods and materials similar or equivalent to those described herein can be used in the practice of the present invention, the preferred methods and materials are now described. All publications mentioned herein are incorporated herein by reference to describe in their entirety.

Methods for Reducing Remnant Cholesterol and Other Lipoprotein Fractions

[0023] The present invention provides methods for reducing serum remnant cholesterol and other lipoprotein fractions in a patient. The methods of the invention comprise selecting a patient who exhibits an elevated serum level of one or more of remnant cholesterol (also referred to as “remnant lipoprotein cholesterol,” “remnant lipoproteins,” or RLP-C), very low density lipoprotein cholesterol (VLDL-C), intermediate density lipoprotein cholesterol (IDL-C), triglycerides (TG), and or Lp(a). In certain embodiments, the methods of the invention comprise selecting a patient who exhibits elevated serum VLDL₁, VLDL₂, VLDL₁₊₂, VLDL₃, LDL₁, LDL₂, LDL₃, LDL₄, LDL₃₊₄, and/or other combinations thereof. The methods of the present invention further comprise administering to the patient a pharmaceutical composition comprising a PCSK9 inhibitor.

[0024] As used herein, the expressions “remnant cholesterol,” “remnant lipoproteins,” “RLP,” and the like, means the cholesterol content of triglyceride-rich lipoproteins, composed of VLDLs and IDLs in the fasting state and of these two lipoproteins together with chylomicron remnants in the nonfasting state. Remnant cholesterol can be calculated as: total cholesterol minus HDL-C minus LDL-C (i.e., non-[HDL-C+LDL-C]). Remnant cholesterol includes VLDL₃and IDL.

[0025] Other lipoprotein fractions include, e.g., LDL₁-C (“large buoyant” LDL), LDL₂-C, LDL₃-C and LDL₄-C (“small dense” LDL). The serum levels of these lipoproteins may be ascertained by standard lipoprotein subfractionation techniques such as, e.g., vertical auto profile (VAP) testing, ion mobility, etc.

[0026] In the context of the present invention, “elevated serum lipoprotein” (e.g., elevated serum remnant cholesterol, elevated serum VLDL-C, elevated serum VLDL₁-C, elevated serum VLDL₂-C, elevated serum VLDL₁₊₂-C, elevated serum VLDL₃-C, elevated serum IDL-C, elevated serum LDL₁-C, elevated serum LDL₂-C, elevated serum LDL₃-C, elevated serum LDL₄-C, elevated serum LDL₃₊₄-C, etc.) means a serum level of the respective lipoprotein greater than about 8 mg/dL. In certain embodiments, a patient is considered to exhibit an elevated serum lipoprotein if the level of the particular lipoprotein measured in the serum of a patient is greater than about 9 mg/dL, 10 mg/dL, 11 mg/dL, 12 mg/dL, 13 mg/dL, 14 mg/dL, 15 mg/dL, 16 mg/dL, 17 mg/dL, 18 mg/dL, 19 mg/dL, 20 mg/dL, 25 mg/dL, 30 mg/dL, 35 mg/dL, 40 mg/dL, 45 mg/dL, 50 mg/dL. The serum lipoprotein level can be measured in a patient post-prandial. In some embodiments, the lipoprotein level is measured after a period of time of fasting (e.g., after fasting for 6 hrs, 8 hrs, 10 hrs, 12 hrs or more). Any clinically acceptable diagnostic method can be used in the context of the present invention to measure serum lipoprotein in a patient.

[0027] According to the present invention, a reduction in serum remnant cholesterol or other lipoprotein subfraction (e.g., VLDL-C, VLDL₁-C, VLDL₂-C, VLDL₁₊₂-C, VLDL₃-C, IDL-C, IDL₁-C, IDL₂-C, IDL₁₊₂-C, LDL₁-C, LDL₂-C, LDL_2a-C, LDL_2b-C, LDL_1+2a-C, LDL₃-C, LDL_3a-C, LDL_3b-C, LDL₄-C, LDL_4a-C, LDL_4b-C, LDL_4c-C, LDL_4a+4b+4c+3b-C, LDL₃₊₄-C, etc.) means that the serum lipoprotein/lipoprotein subfraction level in the patient after receiving a pharmaceutical composition of the invention is reduced by about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, or more, from baseline. As used herein, “baseline level,” when referring to a particular lipoprotein or lipoprotein subfraction, means the level of lipoprotein/lipoprotein subfraction measured in the serum of a subject prior to receiving a pharmaceutical composition of the present invention. The reduction in serum lipoprotein/lipoprotein subfraction resulting from administration of a pharmaceutical composition of the invention may be achieved and/or observed at 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, 4 weeks, 6 weeks, 8 weeks, 10 weeks, 12 weeks, 14 weeks, 16 weeks, 18 weeks, 20 weeks, 22 weeks, or longer, following the initiation of a therapeutic regimen comprising administration of one or more doses of a pharmaceutical composition comprising a PCSK9 inhibitor, examples of which are disclosed elsewhere herein.

[0028] For example, the present invention includes methods for reducing serum remnant cholesterol in a patient by selecting a patient with elevated serum remnant cholesterol, and administering to the patient a pharmaceutical composition comprising a PCSK9 inhibitor, wherein serum remnant cholesterol is reduced in the patient by at least about 35% to about 45% from baseline following administration of the pharmaceutical composition.

[0029] The present invention also includes methods for reducing serum VLDL-C in a patient by selecting a patient with elevated serum VLDL-C, and administering to the patient a pharmaceutical composition comprising a PCSK9 inhibitor, wherein serum VLDL-C is reduced in the patient by at least about 20% to about 28% from baseline following administration of the pharmaceutical composition.

[0030] The present invention also includes methods for reducing serum VLDL₁₊₂-C in a patient by selecting a patient with elevated serum VLDL₁₊₂-C, and administering to the patient a pharmaceutical composition comprising a PCSK9 inhibitor, wherein serum VLDL₁₊₂-C is reduced in the patient by at least about 20% to about 32% from baseline following administration of the pharmaceutical composition.

[0031] The present invention also includes methods for reducing serum VLDL₃-C in a patient by selecting a patient with elevated serum VLDL₃-C, and administering to the patient a pharmaceutical composition comprising a PCSK9 inhibitor, wherein serum VLDL₃-C is reduced in the patient by at least about 20% to about 27% from baseline following administration of the pharmaceutical composition.

[0032] The present invention also includes methods for reducing serum IDL-C in a patient by selecting a patient with elevated serum IDL-C, and administering to the patient a pharmaceutical composition comprising a PCSK9 inhibitor, wherein serum IDL-C is reduced in the patient by at least about 50% to about 56% from baseline following administration of the pharmaceutical composition.

[0033] The present invention also includes methods for reducing serum LDL₁-C in a patient by selecting a patient with elevated serum LDL₁-C, and administering to the patient a pharmaceutical composition comprising a PCSK9 inhibitor, wherein serum LDL₁-C is reduced in the patient by at least about 65% to about 78% from baseline following administration of the pharmaceutical composition.

[0034] The present invention also includes methods for reducing serum LDL₂-C in a patient by selecting a patient with elevated serum LDL₂-C, and administering to the patient a pharmaceutical composition comprising a PCSK9 inhibitor, wherein serum LDL₂-C is reduced in the patient by at least about 75% to about 85% from baseline following administration of the pharmaceutical composition.

[0035] The present invention also includes methods for reducing serum LDL₃₊₄-C in a patient by selecting a patient with elevated serum LDL₃₊₄-C, and administering to the patient a pharmaceutical composition comprising a PCSK9 inhibitor, wherein serum LDL₃₊₄-C is reduced in the patient by at least about 45% to about 70% from baseline following administration of the pharmaceutical composition.

[0036] The present invention also includes methods for reducing apolipoprotein (apo) CII and/or CIII in a patient by selecting a patient with hypercholesterolemia, and administering to the patient a pharmaceutical composition comprising a PCSK9 inhibitor. According to certain embodiments, the patient has non-familial hypercholesterolemia (non-FH); in certain other embodiments, the patient has heterozygous familial hypercholesterolemia (he-FH). According to certain embodiments of this aspect of the invention, apo CII is reduced in the patient by at least about 9% to about 30% from baseline, and apo CIII is reduced in the patient by at least about 20% to about 25%, following administration of the pharmaceutical composition.

[0037] The present invention also includes methods for reducing serum Lp(a) in a patient by selecting a patient with elevated serum Lp(a), and administering to the patient a pharmaceutical composition comprising a PCSK9 inhibitor, wherein serum Lp(a) is reduced in the patient by at least about 10% to about 40% (e.g., about 25%, about 30% or about 35%) from baseline following administration of the pharmaceutical composition.

[0038] The present invention also includes methods for reducing lipoprotein particle concentration in a patient by selecting a patient with hypercholesterolemia and/or elevated serum lipoprotein particle concentration, and administering to the patient a pharmaceutical composition comprising a PCSK9 inhibitor. The methods according to this aspect of the invention are useful for, inter alia, reducing the concentration of low-density lipoprotein particles (LDL-P), intermediate density lipoprotein particles (IDL-P), and very low-density lipoprotein particles (VLDL-P), including methods for reducing the serum concentrations of, e.g., small VLDL-P (diameter 29 to 42 mm); medium VLDL-P (diameter 42 to 60 nm); large VLDL-P (diameter>60 nM); small LDL-P (diameter 18 to 20.5 nm); large LDL-P (diameter 20.5 to 23 nm); and IDL-P (diameter 23 to 29 nm).

Patient Population

[0039] The methods of the present invention are useful for reducing serum remnant cholesterol and other lipoprotein fractions (e.g., VLDL-C, VLDL₁-C, VLDL₂-C, VLDL₁₊₂-C, VLDL₃-C, IDL-C, LDL₁-C, LDL₂-C, LDL₃-C, LDL₄-C, LDL₃₊₄-C, etc.) in a patient. In some instances the patient is otherwise healthy except for exhibiting elevated levels of one or more of the aforementioned serum lipoproteins. For example, the patient may not exhibit any other risk factor of cardiovascular, thrombotic or other diseases or disorders at the time of treatment. In other instances, however, the patient is selected on the basis of being diagnosed with, or at risk of developing, a disease or disorder that is caused by or correlated with elevated serum remnant cholesterol or with elevated serum levels of other lipoproteins or lipoprotein fractions. For example, at the time of, or prior to administration of the pharmaceutical composition of the present invention, the patient may be diagnosed with or identified as being at risk of developing a cardiovascular disease or disorder, such as, e.g., coronary artery disease, acute myocardial infarction, asymptomatic carotid atherosclerosis, stroke, peripheral artery occlusive disease, etc. The cardiovascular disease or disorder, in some instances, is hypercholesterolemia. For example, a patient may be selected for treatment with the methods of the present invention if the patient is diagnosed with or identified as being at risk of developing a hypercholesterolemia condition such as, e.g., heterozygous Familial Hypercholesterolemia (heFH), homozygous Familial Hypercholesterolemia (hoFH), Autosomal Dominant Hypercholesterolemia (ADH, e.g., ADH associated with one or more gain-of-function mutations in the PCSK9 gene), as well as incidences of hypercholesterolemia that are distinct from Familial Hypercholesterolemia (nonFH).

[0040] In other instances, at the time of, or prior to administration of the pharmaceutical composition of the present invention, the patient may be diagnosed with or identified as being at risk of developing an arterial disorder such as cerebrovascular occlusive disease, peripheral vascular disease, peripheral arterial disorder, etc. In certain embodiments, the patient is selected on the basis of being diagnosed with or at risk of developing a combination of two or more of the abovementioned diseases or disorders.

[0041] In yet other instances, the patient who is to be treated with the methods of the present invention is selected on the basis of one or more factors selected from the group consisting of age (e.g., older than 40, 45, 50, 55, 60, 65, 70, 75, or 80 years), race, gender (male or female), exercise habits (e.g., regular exerciser, non-exerciser), other preexisting medical conditions (e.g., type-II diabetes, high blood pressure, etc.), and current medication status (e.g., currently taking statins [e.g., cerivastatin, atorvastatin, simvastatin, pitavastatin, rosuvastatin, fluvastatin, lovastatin, pravastatin, etc.], beta blockers, niacin, etc.). The present invention also includes methods for reducing serum remnant cholesterol and/or other lipoprotein fraction levels in patients who are intolerant of, non-responsive to, or inadequately responsive to conventional statin therapy. Potential patients can be selected/screened on the basis of one or more of these factors (e.g., by questionnaire, diagnostic evaluation, etc.) before being treated with the methods of the present invention.

PCSK9 Inhibitors

[0042] The methods of the present invention comprise administering to a patient a therapeutic composition comprising a PCSK9 inhibitor. As used herein, a “PCSK9 inhibitor” is any agent which binds to or interacts with human PCSK9 and inhibits the normal biological function of PCSK9 in vitro or in vivo. Non-limiting examples of categories of PCSK9 inhibitors include small molecule PCSK9 antagonists, peptide-based PCSK9 antagonists (e.g., “peptibody” molecules), and antibodies or antigen-binding fragments of antibodies that specifically bind human PCSK9.

[0043] The term “human proprotein convertase subtilisin/kexin type 9” or “human PCSK9” or “hPCSK9”, as used herein, refers to PCSK9 having the nucleic acid sequence shown in SEQ ID NO:754 and the amino acid sequence of SEQ ID NO:755, or a biologically active fragment thereof.

[0044] The term “antibody”, as used herein, is intended to refer to immunoglobulin molecules comprising four polypeptide chains, two heavy (H) chains and two light (L) chains inter-connected by disulfide bonds, as well as multimers thereof (e.g., IgM). Each heavy chain comprises a heavy chain variable region (abbreviated herein as HCVR or V_H) and a heavy chain constant region. The heavy chain constant region comprises three domains, C_H1, C_H2 and C_H3. Each light chain comprises a light chain variable region (abbreviated herein as LCVR or V_L) and a light chain constant region. The light chain constant region comprises one domain (C_L1). The V_Hand V_Lregions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDRs), interspersed with regions that are more conserved, termed framework regions (FR). Each V_Hand V_Lis composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. In different embodiments of the invention, the FRs of the anti-PCSK9 antibody (or antigen-binding portion thereof) may be identical to the human germline sequences, or may be naturally or artificially modified. An amino acid consensus sequence may be defined based on a side-by-side analysis of two or more CDRs.

[0045] The term “antibody,” as used herein, also includes antigen-binding fragments of full antibody molecules. The terms “antigen-binding portion” of an antibody, “antigen-binding fragment” of an antibody, and the like, as used herein, include any naturally occurring, enzymatically obtainable, synthetic, or genetically engineered polypeptide or glycoprotein that specifically binds an antigen to form a complex. Antigen-binding fragments of an antibody may be derived, e.g., from full antibody molecules using any suitable standard techniques such as proteolytic digestion or recombinant genetic engineering techniques involving the manipulation and expression of DNA encoding antibody variable and optionally constant domains. Such DNA is known and/or is readily available from, e.g., commercial sources, DNA libraries (including, e.g., phage-antibody libraries), or can be synthesized. The DNA may be sequenced and manipulated chemically or by using molecular biology techniques, for example, to arrange one or more variable and/or constant domains into a suitable configuration, or to introduce codons, create cysteine residues, modify, add or delete amino acids, etc.

[0046] Non-limiting examples of antigen-binding fragments include: (i) Fab fragments; (ii) F(ab′)2 fragments; (iii) Fd fragments; (iv) Fv fragments; (v) single-chain Fv (scFv) molecules; (vi) dAb fragments; and (vii) minimal recognition units consisting of the amino acid residues that mimic the hypervariable region of an antibody (e.g., an isolated complementarity determining region (CDR) such as a CDR3 peptide), or a constrained FR3-CDR3-FR4 peptide. Other engineered molecules, such as domain-specific antibodies, single domain antibodies, domain-deleted antibodies, chimeric antibodies, CDR-grafted antibodies, diabodies, triabodies, tetrabodies, minibodies, nanobodies (e.g. monovalent nanobodies, bivalent nanobodies, etc.), small modular immunopharmaceuticals (SMIPs), and shark variable IgNAR domains, are also encompassed within the expression “antigen-binding fragment,” as used herein.

[0047] An antigen-binding fragment of an antibody will typically comprise at least one variable domain. The variable domain may be of any size or amino acid composition and will generally comprise at least one CDR which is adjacent to or in frame with one or more framework sequences. In antigen-binding fragments having a V_Hdomain associated with a V_Ldomain, the V_Hand V_Ldomains may be situated relative to one another in any suitable arrangement. For example, the variable region may be dimeric and contain V_H-V_H, V_H-V_Lor V_L-V_Ldimers. Alternatively, the antigen-binding fragment of an antibody may contain a monomeric V_Hor V_Ldomain.

[0048] In certain embodiments, an antigen-binding fragment of an antibody may contain at least one variable domain covalently linked to at least one constant domain. Non-limiting, exemplary configurations of variable and constant domains that may be found within an antigen-binding fragment of an antibody of the present invention include: (i) V_H-C_H1; (ii) V_H-C_H2; (iii) V_H-C_H3; (iv) V_H-C_H1-C_H2; (v) V_H-C_H1-C_H2-C_H3; (vi) V_H-C_H2-C_H3; (vii) V_H-C_L; (viii) V_L-C_H1; (ix) V_L-C_H2; (x) V_L-C_H3; (xi) V_L-C_H1-C_H2; (xii) V_L-C_H1-C_H2-C_H3; (xiii) V_L-C_H2-C_H3; and (xiv) V_L-C_L. In any configuration of variable and constant domains, including any of the exemplary configurations listed above, the variable and constant domains may be either directly linked to one another or may be linked by a full or partial hinge or linker region. A hinge region may consist of at least 2 (e.g., 5, 10, 15, 20, 40, 60 or more) amino acids which result in a flexible or semi-flexible linkage between adjacent variable and/or constant domains in a single polypeptide molecule. Moreover, an antigen-binding fragment of an antibody of the present invention may comprise a homo-dimer or hetero-dimer (or other multimer) of any of the variable and constant domain configurations listed above in non-covalent association with one another and/or with one or more monomeric V_Hor V_Ldomain (e.g., by disulfide bond(s)).

[0049] As with full antibody molecules, antigen-binding fragments may be monospecific or multispecific (e.g., bispecific). A multispecific antigen-binding fragment of an antibody will typically comprise at least two different variable domains, wherein each variable domain is capable of specifically binding to a separate antigen or to a different epitope on the same antigen. Any multispecific antibody format, including the exemplary bispecific antibody formats disclosed herein, may be adapted for use in the context of an antigen-binding fragment of an antibody of the present invention using routine techniques available in the art.

[0050] The constant region of an antibody is important in the ability of an antibody to fix complement and mediate cell-dependent cytotoxicity. Thus, the isotype of an antibody may be selected on the basis of whether it is desirable for the antibody to mediate cytotoxicity.

[0051] The term “human antibody”, as used herein, is intended to include antibodies having variable and constant regions derived from human germline immunoglobulin sequences. The human antibodies of the invention may nonetheless include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo), for example in the CDRs and in particular CDR3. However, the term “human antibody”, as used herein, is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences.

[0052] The term “recombinant human antibody”, as used herein, is intended to include all human antibodies that are prepared, expressed, created or isolated by recombinant means, such as antibodies expressed using a recombinant expression vector transfected into a host cell (described further below), antibodies isolated from a recombinant, combinatorial human antibody library (described further below), antibodies isolated from an animal (e.g., a mouse) that is transgenic for human immunoglobulin genes (see e.g., Taylor et al. (1992) Nucl. Acids Res. 20:6287-6295) or antibodies prepared, expressed, created or isolated by any other means that involves splicing of human immunoglobulin gene sequences to other DNA sequences. Such recombinant human antibodies have variable and constant regions derived from human germline immunoglobulin sequences. In certain embodiments, however, such recombinant human antibodies are subjected to in vitro mutagenesis (or, when an animal transgenic for human Ig sequences is used, in vivo somatic mutagenesis) and thus the amino acid sequences of the V_Hand V_Lregions of the recombinant antibodies are sequences that, while derived from and related to human germline V_Hand V_Lsequences, may not naturally exist within the human antibody germline repertoire in vivo.

[0053] Human antibodies can exist in two forms that are associated with hinge heterogeneity. In one form, an immunoglobulin molecule comprises a stable four chain construct of approximately 150-160 kDa in which the dimers are held together by an interchain heavy chain disulfide bond. In a second form, the dimers are not linked via inter-chain disulfide bonds and a molecule of about 75-80 kDa is formed composed of a covalently coupled light and heavy chain (half-antibody). These forms have been extremely difficult to separate, even after affinity purification.

[0054] The frequency of appearance of the second form in various intact IgG isotypes is due to, but not limited to, structural differences associated with the hinge region isotype of the antibody. A single amino acid substitution in the hinge region of the human IgG4 hinge can significantly reduce the appearance of the second form (Angal et al. (1993) Molecular Immunology 30:105) to levels typically observed using a human IgG1 hinge. The instant invention encompasses antibodies having one or more mutations in the hinge, C_H2 or C_H3 region which may be desirable, for example, in production, to improve the yield of the desired antibody form.

[0055] An “isolated antibody,” as used herein, means an antibody that has been identified and separated and/or recovered from at least one component of its natural environment. For example, an antibody that has been separated or removed from at least one component of an organism, or from a tissue or cell in which the antibody naturally exists or is naturally produced, is an “isolated antibody” for purposes of the present invention. An isolated antibody also includes an antibody in situ within a recombinant cell. Isolated antibodies are antibodies that have been subjected to at least one purification or isolation step. According to certain embodiments, an isolated antibody may be substantially free of other cellular material and/or chemicals.

[0056] The term “specifically binds,” or the like, means that an antibody or antigen-binding fragment thereof forms a complex with an antigen that is relatively stable under physiologic conditions. Methods for determining whether an antibody specifically binds to an antigen are well known in the art and include, for example, equilibrium dialysis, surface plasmon resonance, and the like. For example, an antibody that “specifically binds” PCSK9, as used in the context of the present invention, includes antibodies that bind PCSK9 or portion thereof with a K_Dof less than about 1000 nM, less than about 500 nM, less than about 300 nM, less than about 200 nM, less than about 100 nM, less than about 90 nM, less than about 80 nM, less than about 70 nM, less than about 60 nM, less than about 50 nM, less than about 40 nM, less than about 30 nM, less than about 20 nM, less than about 10 nM, less than about 5 nM, less than about 4 nM, less than about 3 nM, less than about 2 nM, less than about 1 nM or less than about 0.5 nM, as measured in a surface plasmon resonance assay. An isolated antibody that specifically binds human PCSK9, however, have cross-reactivity to other antigens, such as PCSK9 molecules from other (non-human) species.

[0057] The anti-PCSK9 antibodies useful for the methods of the present invention may comprise one or more amino acid substitutions, insertions and/or deletions in the framework and/or CDR regions of the heavy and light chain variable domains as compared to the corresponding germline sequences from which the antibodies were derived. Such mutations can be readily ascertained by comparing the amino acid sequences disclosed herein to germline sequences available from, for example, public antibody sequence databases. The present invention includes methods involving the use of antibodies, and antigen-binding fragments thereof, which are derived from any of the amino acid sequences disclosed herein, wherein one or more amino acids within one or more framework and/or CDR regions are mutated to the corresponding residue(s) of the germline sequence from which the antibody was derived, or to the corresponding residue(s) of another human germline sequence, or to a conservative amino acid substitution of the corresponding germline residue(s) (such sequence changes are referred to herein collectively as “germline mutations”). A person of ordinary skill in the art, starting with the heavy and light chain variable region sequences disclosed herein, can easily produce numerous antibodies and antigen-binding fragments which comprise one or more individual germline mutations or combinations thereof. In certain embodiments, all of the framework and/or CDR residues within the V_Hand/or V_Ldomains are mutated back to the residues found in the original germline sequence from which the antibody was derived. In other embodiments, only certain residues are mutated back to the original germline sequence, e.g., only the mutated residues found within the first 8 amino acids of FR1 or within the last 8 amino acids of FR4, or only the mutated residues found within CDR1, CDR2 or CDR3. In other embodiments, one or more of the framework and/or CDR residue(s) are mutated to the corresponding residue(s) of a different germline sequence (i.e., a germline sequence that is different from the germline sequence from which the antibody was originally derived). Furthermore, the antibodies of the present invention may contain any combination of two or more germline mutations within the framework and/or CDR regions, e.g., wherein certain individual residues are mutated to the corresponding residue of a particular germline sequence while certain other residues that differ from the original germline sequence are maintained or are mutated to the corresponding residue of a different germline sequence. Once obtained, antibodies and antigen-binding fragments that contain one or more germline mutations can be easily tested for one or more desired property such as, improved binding specificity, increased binding affinity, improved or enhanced antagonistic or agonistic biological properties (as the case may be), reduced immunogenicity, etc. The use of antibodies and antigen-binding fragments obtained in this general manner are encompassed within the present invention.

[0058] The present invention also includes methods involving the use of anti-PCSK9 antibodies comprising variants of any of the HCVR, LCVR, and/or CDR amino acid sequences disclosed herein having one or more conservative substitutions. For example, the present invention includes the use of anti-PCSK9 antibodies having HCVR, LCVR, and/or CDR amino acid sequences with, e.g., 10 or fewer, 8 or fewer, 6 or fewer, 4 or fewer, etc. conservative amino acid substitutions relative to any of the HCVR, LCVR, and/or CDR amino acid sequences disclosed herein.

[0059] The term “surface plasmon resonance”, as used herein, refers to an optical phenomenon that allows for the analysis of real-time interactions by detection of alterations in protein concentrations within a biosensor matrix, for example using the BIAcore™ system (Biacore Life Sciences division of GE Healthcare, Piscataway, N.J.).

[0060] The term “K_D”, as used herein, is intended to refer to the equilibrium dissociation constant of a particular antibody-antigen interaction.

[0061] The term “epitope” refers to an antigenic determinant that interacts with a specific antigen binding site in the variable region of an antibody molecule known as a paratope. A single antigen may have more than one epitope. Thus, different antibodies may bind to different areas on an antigen and may have different biological effects. Epitopes may be either conformational or linear. A conformational epitope is produced by spatially juxtaposed amino acids from different segments of the linear polypeptide chain. A linear epitope is one produced by adjacent amino acid residues in a polypeptide chain. In certain circumstance, an epitope may include moieties of saccharides, phosphoryl groups, or sulfonyl groups on the antigen.

[0062] According to certain embodiments, the anti-PCSK9 antibody used in the methods of the present invention is an antibody with pH-dependent binding characteristics. As used herein, the expression “pH-dependent binding” means that the antibody or antigen-binding fragment thereof exhibits “reduced binding to PCSK9 at acidic pH as compared to neutral pH” (for purposes of the present disclosure, both expressions may be used interchangeably). For the example, antibodies “with pH-dependent binding characteristics” includes antibodies and antigen-binding fragments thereof that bind PCSK9 with higher affinity at neutral pH than at acidic pH. In certain embodiments, the antibodies and antigen-binding fragments of the present invention bind PCSK9 with at least 3, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, or more times higher affinity at neutral pH than at acidic pH.

[0063] According to this aspect of the invention, the anti-PCSK9 antibodies with pH-dependent binding characteristics may possess one or more amino acid variations relative to the parental anti-PCSK9 antibody. For example, an anti-PCSK9 antibody with pH-dependent binding characteristics may contain one or more histidine substitutions or insertions, e.g., in one or more CDRs of a parental anti-PCSK9 antibody. Thus, according to certain embodiments of the present invention, methods are provided comprising administering an anti-PCSK9 antibody which comprises CDR amino acid sequences (e.g., heavy and light chain CDRs) which are identical to the CDR amino acid sequences of a parental anti-PCSK9 antibody, except for the substitution of one or more amino acids of one or more CDRs of the parental antibody with a histidine residue. The anti-PCSK9 antibodies with pH-dependent binding may possess, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or more histidine substitutions, either within a single CDR of a parental antibody or distributed throughout multiple (e.g., 2, 3, 4, 5, or 6) CDRs of a parental anti-PCSK9 antibody. For example, the present invention includes the use of anti-PCSK9 antibodies with pH-dependent binding comprising one or more histidine substitutions in HCDR1, one or more histidine substitutions in HCDR2, one or more histidine substitutions in HCDR3, one or more histidine substitutions in LCDR1, one or more histidine substitutions in LCDR2, and/or one or more histidine substitutions in LCDR3, of a parental anti-PCSK9 antibody.

[0064] As used herein, the expression “acidic pH” means a pH of 6.0 or less (e.g., less than about 6.0, less than about 5.5, less than about 5.0, etc.). The expression “acidic pH” includes pH values of about 6.0, 5.95, 5.90, 5.85, 5.8, 5.75, 5.7, 5.65, 5.6, 5.55, 5.5, 5.45, 5.4, 5.35, 5.3, 5.25, 5.2, 5.15, 5.1, 5.05, 5.0, or less. As used herein, the expression “neutral pH” means a pH of about 7.0 to about 7.4. The expression “neutral pH” includes pH values of about 7.0, 7.05, 7.1, 7.15, 7.2, 7.25, 7.3, 7.35, and 7.4.

Preparation of Human Antibodies

[0065] Methods for generating human antibodies in transgenic mice are known in the art. Any such known methods can be used in the context of the present invention to make human antibodies that specifically bind to human PCSK9.

[0066] Using VELOCIMMUNE™ technology (see, for example, U.S. Pat. No. 6,596,541, Regeneron Pharmaceuticals) or any other known method for generating monoclonal antibodies, high affinity chimeric antibodies to PCSK9 are initially isolated having a human variable region and a mouse constant region. The VELOCIMMUNE® technology involves generation of a transgenic mouse having a genome comprising human heavy and light chain variable regions operably linked to endogenous mouse constant region loci such that the mouse produces an antibody comprising a human variable region and a mouse constant region in response to antigenic stimulation. The DNA encoding the variable regions of the heavy and light chains of the antibody are isolated and operably linked to DNA encoding the human heavy and light chain constant regions. The DNA is then expressed in a cell capable of expressing the fully human antibody.

[0067] Generally, a VELOCIMMUNE® mouse is challenged with the antigen of interest, and lymphatic cells (such as B-cells) are recovered from the mice that express antibodies. The lymphatic cells may be fused with a myeloma cell line to prepare immortal hybridoma cell lines, and such hybridoma cell lines are screened and selected to identify hybridoma cell lines that produce antibodies specific to the antigen of interest. DNA encoding the variable regions of the heavy chain and light chain may be isolated and linked to desirable isotypic constant regions of the heavy chain and light chain. Such an antibody protein may be produced in a cell, such as a CHO cell. Alternatively, DNA encoding the antigen-specific chimeric antibodies or the variable domains of the light and heavy chains may be isolated directly from antigen-specific lymphocytes.

[0068] Initially, high affinity chimeric antibodies are isolated having a human variable region and a mouse constant region. The antibodies are characterized and selected for desirable characteristics, including affinity, selectivity, epitope, etc, using standard procedures known to those skilled in the art. The mouse constant regions are replaced with a desired human constant region to generate the fully human antibody of the invention, for example wild-type or modified IgG1 or IgG4. While the constant region selected may vary according to specific use, high affinity antigen-binding and target specificity characteristics reside in the variable region.

[0069] In general, the antibodies that can be used in the methods of the present invention possess high affinities, as described above, when measured by binding to antigen either immobilized on solid phase or in solution phase. The mouse constant regions are replaced with desired human constant regions to generate the fully human antibodies of the invention. While the constant region selected may vary according to specific use, high affinity antigen-binding and target specificity characteristics reside in the variable region.

[0070] Specific examples of human antibodies or antigen-binding fragments of antibodies that specifically bind PCSK9 which can be used in the context of the methods of the present invention include any antibody or antigen-binding fragment which comprises the three heavy chain CDRs (HCDR1, HCDR2 and HCDR3) contained within a heavy chain variable region (HCVR) having an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 18, 22, 26, 42, 46, 50, 66, 70, 74, 90, 94, 98, 114, 118, 122, 138, 142, 146, 162, 166, 170, 186, 190, 194, 210, 214, 218, 234, 238, 242, 258, 262, 266, 282, 286, 290, 306, 310, 314, 330, 334, 338, 354, 358, 362, 378, 382, 386, 402, 406, 410, 426, 430, 434, 450, 454, 458, 474, 478, 482, 498, 502, 506, 522, 526, 530, 546, 550, 554, 570, 574, 578, 594, 598, 602, 618, 622, 626, 642, 646, 650, 666, 670, 674, 690, 694, 698, 714, 718, 722, 738 and 742, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity. The antibody or antigen-binding fragment may comprise the three light chain CDRs (LCVR1, LCVR2, LCVR3) contained within a light chain variable region (LCVR) having an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 20, 24, 34, 44, 48, 58, 68, 72, 82, 92, 96, 106, 116, 120, 130, 140, 144, 154, 164, 168, 178, 188, 192, 202, 212, 216, 226, 236, 240, 250, 260, 264, 274, 284, 288, 298, 308, 312, 322, 332, 336, 346, 356, 360, 370, 380, 384, 394, 404, 408, 418, 428, 432, 442, 452, 456, 466, 476, 480, 490, 500, 504, 514, 524, 528, 538, 548, 552, 562, 572, 576, 586, 596, 600, 610, 620, 624, 634, 644, 648, 658, 668, 672, 682, 692, 696, 706, 716, 720, 730, 740 and 744, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity.

[0071] In certain embodiments of the present invention, the antibody or antigen-binding fragment thereof comprises the six CDRs (HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3) from the heavy and light chain variable region amino acid sequence pairs (HCVR/LCVR) selected from the group consisting of SEQ ID NOs: 2/10, 18/20, 22/24, 26/34, 42/44, 46/48, 50/58, 66/68, 70/72, 74/82, 90/92, 94/96, 98/106, 114/116, 118/120, 122/130, 138/140, 142/144, 146/154, 162/164, 166/168, 170/178, 186/188, 190/192, 194/202, 210/212, 214/216, 218/226, 234/236, 238/240, 242/250, 258/260, 262/264, 266/274, 282/284, 286/288, 290/298, 306/308, 310/312, 314/322, 330/332, 334/336, 338/346, 354/356, 358/360, 362/370, 378/380, 382/384, 386/394, 402/404, 406/408, 410/418, 426/428, 430/432, 434/442, 450/452, 454/456, 458/466, 474/476, 478/480, 482/490, 498/500, 502/504, 506/514, 522/524, 526/528, 530/538, 546/548, 550/552, 554/562, 570/572, 574/576, 578/586, 594/596, 598/600, 602/610, 618/620, 622/624, 626/634, 642/644, 646/648, 650/658, 666/668, 670/672, 674/682, 690/692, 694/696, 698/706, 714/716, 718/720, 722/730, 738/740 and 742/744.

[0072] In certain embodiments of the present invention, the anti-PCSK9 antibody, or antigen-binding fragment thereof, that can be used in the methods of the present invention has HCDR1/HCDR2/HCDR3/LCDR1/LCDR2/LCDR3 amino acid sequences selected from SEQ ID NOs: 76/78/80/84/86/88 (mAb316P) and 220/222/224/228/230/232 (mAb300N) (See US Patent App. Publ No. 2010/0166768).

[0073] In certain embodiments of the present invention, the antibody or antigen-binding fragment thereof comprises HCVR/LCVR amino acid sequence pairs selected from the group consisting of SEQ ID NOs: 2/10, 18/20, 22/24, 26/34, 42/44, 46/48, 50/58, 66/68, 70/72, 74/82, 90/92, 94/96, 98/106, 114/116, 118/120, 122/130, 138/140, 142/144, 146/154, 162/164, 166/168, 170/178, 186/188, 190/192, 194/202, 210/212, 214/216, 218/226, 234/236, 238/240, 242/250, 258/260, 262/264, 266/274, 282/284, 286/288, 290/298, 306/308, 310/312, 314/322, 330/332, 334/336, 338/346, 354/356, 358/360, 362/370, 378/380, 382/384, 386/394, 402/404, 406/408, 410/418, 426/428, 430/432, 434/442, 450/452, 454/456, 458/466, 474/476, 478/480, 482/490, 498/500, 502/504, 506/514, 522/524, 526/528, 530/538, 546/548, 550/552, 554/562, 570/572, 574/576, 578/586, 594/596, 598/600, 602/610, 618/620, 622/624, 626/634, 642/644, 646/648, 650/658, 666/668, 670/672, 674/682, 690/692, 694/696, 698/706, 714/716, 718/720, 722/730, 738/740 and 742/744.

Pharmaceutical Compositions and Methods of Administration

[0074] The present invention includes methods which comprise administering a PCSK9 inhibitor to a patient, wherein the PCSK9 inhibitor is contained within a pharmaceutical composition. The pharmaceutical compositions of the invention are formulated with suitable carriers, excipients, and other agents that provide suitable transfer, delivery, tolerance, and the like. A multitude of appropriate formulations can be found in the formulary known to all pharmaceutical chemists: Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa. These formulations include, for example, powders, pastes, ointments, jellies, waxes, oils, lipids, lipid (cationic or anionic) containing vesicles (such as LIPOFECTIN™), DNA conjugates, anhydrous absorption pastes, oil-in-water and water-in-oil emulsions, emulsions carbowax (polyethylene glycols of various molecular weights), semi-solid gels, and semi-solid mixtures containing carbowax. See also Powell et al. “Compendium of excipients for parenteral formulations” PDA (1998) J Pharm Sci Technol 52:238-311.

[0075] Various delivery systems are known and can be used to administer the pharmaceutical composition of the invention, e.g., encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the mutant viruses, receptor mediated endocytosis (see, e.g., Wu et al., 1987, J. Biol. Chem. 262:4429-4432). Methods of administration include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The composition may be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents.

[0076] A pharmaceutical composition of the present invention can be delivered subcutaneously or intravenously with a standard needle and syringe. In addition, with respect to subcutaneous delivery, a pen delivery device readily has applications in delivering a pharmaceutical composition of the present invention. Such a pen delivery device can be reusable or disposable. A reusable pen delivery device generally utilizes a replaceable cartridge that contains a pharmaceutical composition. Once all of the pharmaceutical composition within the cartridge has been administered and the cartridge is empty, the empty cartridge can readily be discarded and replaced with a new cartridge that contains the pharmaceutical composition. The pen delivery device can then be reused. In a disposable pen delivery device, there is no replaceable cartridge. Rather, the disposable pen delivery device comes prefilled with the pharmaceutical composition held in a reservoir within the device. Once the reservoir is emptied of the pharmaceutical composition, the entire device is discarded.

[0077] Numerous reusable pen and autoinjector delivery devices have applications in the subcutaneous delivery of a pharmaceutical composition of the present invention. Examples include, but are not limited to AUTOPEN™ (Owen Mumford, Inc., Woodstock, UK), DISETRONIC™ pen (Disetronic Medical Systems, Bergdorf, Switzerland), HUMALOG MIX 75/25™ pen, HUMALOG™ pen, HUMALIN 70/30™ pen (Eli Lilly and Co., Indianapolis, Ind.), NOVOPEN™ I, II and III (Novo Nordisk, Copenhagen, Denmark), NOVOPEN JUNIOR™ (Novo Nordisk, Copenhagen, Denmark), BD™ pen (Becton Dickinson, Franklin Lakes, N.J.), OPTIPEN™, OPTIPEN PRO™, OPTIPEN STARLET™, and OPTICLIK™ (sanofi-aventis, Frankfurt, Germany), to name only a few. Examples of disposable pen delivery devices having applications in subcutaneous delivery of a pharmaceutical composition of the present invention include, but are not limited to the SOLOSTAR™ pen (sanofi-aventis), the FLEXPEN™ (Novo Nordisk), and the KWIKPEN™ (Eli Lilly), the SURECLICK™ Autoinjector (Amgen, Thousand Oaks, Calif.), the PENLET™ (Haselmeier, Stuttgart, Germany), the EPIPEN (Dey, L. P.), and the HUMIRA™ Pen (Abbott Labs, Abbott Park Ill.), to name only a few.

[0078] In certain situations, the pharmaceutical composition can be delivered in a controlled release system. In one embodiment, a pump may be used (see Langer, supra; Sefton, 1987, CRC Crit. Ref. Biomed. Eng. 14:201). In another embodiment, polymeric materials can be used; see, Medical Applications of Controlled Release, Langer and Wise (eds.), 1974, CRC Pres., Boca Raton, Fla. In yet another embodiment, a controlled release system can be placed in proximity of the composition's target, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, 1984, in Medical Applications of Controlled Release, supra, vol. 2, pp. 115-138). Other controlled release systems are discussed in the review by Langer, 1990, Science 249:1527-1533.

[0079] The injectable preparations may include dosage forms for intravenous, subcutaneous, intracutaneous and intramuscular injections, drip infusions, etc. These injectable preparations may be prepared by known methods. For example, the injectable preparations may be prepared, e.g., by dissolving, suspending or emulsifying the antibody or its salt described above in a sterile aqueous medium or an oily medium conventionally used for injections. As the aqueous medium for injections, there are, for example, physiological saline, an isotonic solution containing glucose and other auxiliary agents, etc., which may be used in combination with an appropriate solubilizing agent such as an alcohol (e.g., ethanol), a polyalcohol (e.g., propylene glycol, polyethylene glycol), a nonionic surfactant [e.g., polysorbate 80, HCO-50 (polyoxyethylene (50 mol) adduct of hydrogenated castor oil)], etc. As the oily medium, there are employed, e.g., sesame oil, soybean oil, etc., which may be used in combination with a solubilizing agent such as benzyl benzoate, benzyl alcohol, etc. The injection thus prepared is preferably filled in an appropriate ampoule.

[0080] Advantageously, the pharmaceutical compositions for oral or parenteral use described above are prepared into dosage forms in a unit dose suited to fit a dose of the active ingredients. Such dosage forms in a unit dose include, for example, tablets, pills, capsules, injections (ampoules), suppositories, etc.

Dosage

[0081] The amount of PCSK9 inhibitor (e.g., anti-PCSK9 antibody) administered to a subject according to the methods of the present invention is, generally, a therapeutically effective amount. As used herein, the phrase “therapeutically effective amount” means a dose of PCSK9 inhibitor that results in a detectable reduction (at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, or more from baseline) in one or more parameters selected from the group consisting of remnant cholesterol (RLP-C), VLDL-C, VLDL₁-C, VLDL₂-C, VLDL₁₊₂-C, VLDL₃-C, IDL-C, LDL₁-C, LDL₂-C, LDL₃-C, LDL₄-C, LDL₃₊₄-C. Alternatively, animal models can be used to establish whether a particular amount of a candidate PCSK9 inhibitor is a therapeutically effective amount.

[0082] In the case of an anti-PCSK9 antibody, a therapeutically effective amount can be from about 0.05 mg to about 600 mg, e.g., about 0.05 mg, about 0.1 mg, about 1.0 mg, about 1.5 mg, about 2.0 mg, about 10 mg, about 20 mg, about 30 mg, about 40 mg, about 50 mg, about 60 mg, about 70 mg, about 75 mg, about 80 mg, about 90 mg, about 100 mg, about 110 mg, about 120 mg, about 130 mg, about 140 mg, about 150 mg, about 160 mg, about 170 mg, about 180 mg, about 190 mg, about 200 mg, about 210 mg, about 220 mg, about 230 mg, about 240 mg, about 250 mg, about 260 mg, about 270 mg, about 280 mg, about 290 mg, about 300 mg, about 310 mg, about 320 mg, about 330 mg, about 340 mg, about 350 mg, about 360 mg, about 370 mg, about 380 mg, about 390 mg, about 400 mg, about 410 mg, about 420 mg, about 430 mg, about 440 mg, about 450 mg, about 460 mg, about 470 mg, about 480 mg, about 490 mg, about 500 mg, about 510 mg, about 520 mg, about 530 mg, about 540 mg, about 550 mg, about 560 mg, about 570 mg, about 580 mg, about 590 mg, or about 600 mg, of the anti-PCSK9 antibody.

[0083] The amount of anti-PCSK9 antibody contained within the individual doses may be expressed in terms of milligrams of antibody per kilogram of patient body weight (i.e., mg/kg). For example, the anti-PCSK9 antibody may be administered to a patient at a dose of about 0.0001 to about 10 mg/kg of patient body weight.

Combination Therapies

[0084] The methods of the present invention, according to certain embodiments, may comprise administering a pharmaceutical composition comprising an anti-PCSK9 antibody to a patient who is on a therapeutic regimen for the treatment of hypercholesterolemia at the time of, or just prior to, administration of the pharmaceutical composition of the invention. For example, a patient who has previously been diagnosed with hypercholesterolemia may have been prescribed and is taking a stable therapeutic regimen of another drug prior to and/or concurrent with administration of a pharmaceutical composition comprising an anti-PCSK9 antibody. The prior or concurrent therapeutic regimen may comprise, e.g., (1) an agent which induces a cellular depletion of cholesterol synthesis by inhibiting 3-hydroxy-3-methylglutaryl (HMG)-coenzyme A (CoA) reductase, such as a statin (e.g., cerivastatin, atorvastatin, simvastatin, pitavastatin, rosuvastatin, fluvastatin, lovastatin, pravastatin, etc.); (2) an agent which inhibits cholesterol uptake and or bile acid re-absorption; (3) an agent which increase lipoprotein catabolism (such as niacin); and/or (4) activators of the LXR transcription factor that plays a role in cholesterol elimination such as 22-hydroxycholesterol. In certain embodiments, the patient, prior to or concurrent with administration of an anti-PCSK9 antibody is on a fixed combination of therapeutic agents such as ezetimibe plus simvastatin; a statin with a bile resin (e.g., cholestyramine, colestipol, colesevelam); niacin plus a statin (e.g., niacin with lovastatin); or with other lipid lowering agents such as omega-3-fatty acid ethyl esters (for example, omacor).

Administration Regimens

[0085] According to certain embodiments of the present invention, multiple doses of a PCSK9 inhibitor (i.e., a pharmaceutical composition comprising a PCSK9 inhibitor) may be administered to a subject over a defined time course. The methods according to this aspect of the invention comprise sequentially administering to a subject multiple doses of a PCSK9 inhibitor. As used herein, “sequentially administering” means that each dose of PCSK9 inhibitor is administered to the subject at a different point in time, e.g., on different days separated by a predetermined interval (e.g., hours, days, weeks or months). The present invention includes methods which comprise sequentially administering to the patient a single initial dose of a PCSK9 inhibitor, followed by one or more secondary doses of the PCSK9 inhibitor, and optionally followed by one or more tertiary doses of the PCSK9 inhibitor.

[0086] The terms “initial dose,” “secondary doses,” and “tertiary doses,” refer to the temporal sequence of administration of the individual doses of a pharmaceutical composition comprising a PCSK9 inhibitor. Thus, the “initial dose” is the dose which is administered at the beginning of the treatment regimen (also referred to as the “baseline dose”); the “secondary doses” are the doses which are administered after the initial dose; and the “tertiary doses” are the doses which are administered after the secondary doses. The initial, secondary, and tertiary doses may all contain the same amount of the PCSK9 inhibitor, but generally may differ from one another in terms of frequency of administration. In certain embodiments, however, the amount of PCSK9 inhibitor contained in the initial, secondary and/or tertiary doses varies from one another (e.g., adjusted up or down as appropriate) during the course of treatment. In certain embodiments, two or more (e.g., 2, 3, 4, or 5) doses are administered at the beginning of the treatment regimen as “loading doses” followed by subsequent doses that are administered on a less frequent basis (e.g., “maintenance doses”).

[0087] According to exemplary embodiments of the present invention, each secondary and/or tertiary dose is administered 1 to 26 (e.g., 1, 1½, 2, 2½, 3, 3½, 4, 4½, 5, 5½, 6, 6½, 7, 7½, 8, 8½, 9, 9½, 10, 10½, 11, 11½, 12, 12½, 13, 13½, 14, 14½, 15, 15½, 16, 16½, 17, 17½, 18, 18½, 19, 19½, 20, 20½, 21, 21½, 22, 22½, 23, 23½, 24, 24½, 25, 25½, 26, 26½, or more) weeks after the immediately preceding dose. The phrase “the immediately preceding dose,” as used herein, means, in a sequence of multiple administrations, the dose of antigen-binding molecule which is administered to a patient prior to the administration of the very next dose in the sequence with no intervening doses.

[0088] The methods according to this aspect of the invention may comprise administering to a patient any number of secondary and/or tertiary doses of a PCSK9 inhibitor. For example, in certain embodiments, only a single secondary dose is administered to the patient. In other embodiments, two or more (e.g., 2, 3, 4, 5, 6, 7, 8, or more) secondary doses are administered to the patient. Likewise, in certain embodiments, only a single tertiary dose is administered to the patient. In other embodiments, two or more (e.g., 2, 3, 4, 5, 6, 7, 8, or more) tertiary doses are administered to the patient.

[0089] In embodiments involving multiple secondary doses, each secondary dose may be administered at the same frequency as the other secondary doses. For example, each secondary dose may be administered to the patient 1 to 2, 4, 6, 8 or more weeks after the immediately preceding dose. Similarly, in embodiments involving multiple tertiary doses, each tertiary dose may be administered at the same frequency as the other tertiary doses. For example, each tertiary dose may be administered to the patient 1 to 2, 4, 6, 8 or more weeks after the immediately preceding dose. Alternatively, the frequency at which the secondary and/or tertiary doses are administered to a patient can vary over the course of the treatment regimen. The frequency of administration may also be adjusted during the course of treatment by a physician depending on the needs of the individual patient following clinical examination.

[0090] The present invention includes administration regimens comprising an up-titration option (also referred to herein as “dose modification”). As used herein, an “up-titration option” means that, after receiving a particular number of doses of a PCSK9 inhibitor, if a patient has not achieved a specified reduction in one or more defined therapeutic parameters, the dose of the PCSK9 inhibitor is thereafter increased. For example, in the case of a therapeutic regimen comprising administration of 75 mg doses of an anti-PCSK9 antibody to a patient at a frequency of once every two weeks, if after 8 weeks (i.e., 5 doses administered at Week 0, Week 2 and Week 4, Week 6 and Week 8), the patient has not achieved a serum LDL-C concentration of less than 70 mg/dL, then the dose of anti-PCSK9 antibody is increased to e.g., 150 mg administered once every two weeks thereafter (e.g., starting at Week 10 or Week 12, or later).

EXAMPLES

[0091] The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the methods and compositions of the invention, and are not intended to limit the scope of what the inventors regard as their invention. Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperature, etc.) but some experimental errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, molecular weight is average molecular weight, temperature is in degrees Centigrade, and pressure is at or near atmospheric.

Example 1. Generation of Human Antibodies to Human PCSK9

[0092] Human anti-PCSK9 antibodies were generated as described in U.S. Pat. No. 8,062,640. The exemplary PCSK9 inhibitor used in the following Example is the human anti-PCSK9 antibody designated “mAb316P” (also referred to in the scientific literature as “alirocumab”). mAb316P has the following amino acid sequence characteristics: heavy chain variable region (HCVR) comprising SEQ ID NO:90; light chain variable domain (LCVR) comprising SEQ ID NO:92; heavy chain complementarity determining region 1 (HCDR1) comprising SEQ ID NO:76; HCDR2 comprising SEQ ID NO:78; HCDR3 comprising SEQ ID NO:80; light chain complementarity determining region 1 (LCDR1) comprising SEQ ID NO:84; LCDR2 comprising SEQ ID NO:86; and LCDR3 comprising SEQ ID NO:88.

Example 2: Dynamics Between Anti-PCSK9 Antibody Levels and Low-Density Lipoprotein Cholesterol (LDL-C) Levels

Introduction

[0093] Descriptive analyses of pharmacokinetic and pharmacodynamic data from Phase I and II studies of mAb316P were conducted to characterize relationships between mAb316P, PCSK9 and LDL-C levels. Three different clinical trials were included in this analysis:

[0094] (1) Single-Dose Study:

[0095] Phase I, single-dose study in healthy subjects not receiving background statin therapy in which subjects received single subcutaneous (SC) doses of mAb316P 50, 100, 150, and 250 mg, or placebo.

[0096] (2) Multiple-Dose Study:

[0097] A Phase I study in cohorts of heterozygous familial hypercholesterolemia (HeFH) and non-familial hypercholesterolemia (FH) patients receiving atorvastatin therapy and non-FH patients receiving diet alone. Patients receiving atorvastatin were randomized to mAb316P (50, 100, or 150 mg) or placebo administered SC on Days 1, 29, and 43. Non-FH patients receiving diet alone were randomized to mAb316P 150 mg or placebo administered SC on Days 1 and 29.

[0098] (3) Phase II Study:

[0099] A 12-week study in hypercholesterolemic patients receiving atorvastatin therapy: patients randomized to mAb316P 50, 100, or 150 mg SC every 2 weeks (Q2W), 200 or 300 mg SC every 4 weeks (Q4W), or placebo.

Results

[0100] Single administration of mAb316P 150 mg SC rapidly bound to and rapidly reduced circulating free PCSK9 levels; this was followed by a drop in LDL-C. The return of free PCSK9 towards starting levels was noted to precede the return of LDL-C levels (FIG. 1). Free PCSK9 levels reached nadir by Day 3 following administration of mAb316P 50, 100, or 150 mg SC in HeFH or non-FH patients (FIG. 2). The return of free PCSK9 to starting levels was slower in the patients who received mAb316P plus diet alone versus patients who received mAb316P plus atorvastatin (FIG. 2). The greatest mean LDL-C reductions were recorded on Day 8 for the 50 mg and 100 mg doses and Day 15 for the 150 mg dose; this delay relative to free PCSK9 concentrations may possibly be due to the time required for the production of new LDL-C receptors. A representative hysteresis curve showing the relationship between total mAb316P and LDL-C following administration of the 150 mg dose is shown in FIG. 3.

[0101] Higher baseline free PCSK9 levels were observed in patients taking statins as compared with diet alone (FIG. 4). There was increased target-mediated clearance of mAb316P with concurrent statin therapy (due to higher free PCSK9 levels, likely reflective of an increase in production rate) compared with mAb316P and diet therapy alone. This appeared to affect the duration of LDL-C lowering over a 4-week dosing interval (Days 1 to 29), which was reduced with concurrent statin therapy versus diet only; however, this effect was not seen over the 2-week dosing interval (Days 29 to 43) (FIG. 5).

[0102] In hypercholesterolemic (non-FH) patients receiving concomitant statin therapy, mAb316P Q2W resulted in uniformly strong LDL-C lowering at 12 weeks. Patients on Q2W dosing regimens exhibited lower variability in the LDL-C response at Week 12 versus Q4W dosing (FIG. 6); coefficient of variation 16% versus 49% for 150 mg Q2W and 300 mg Q4W, respectively.

Conclusions

[0103] Dynamics were apparent between mAb316P, free PCSK9 and LDL-C levels. mAb316P treatment resulted in reductions in free PCSK9 levels within 3 days of dosing and peak reductions in LDL-C_8-15days after dosing.

[0104] The clearance of mAb316P was accelerated by its binding to free PCSK9 (target-mediated clearance). Lower levels of free PCSK9 resulted in a longer duration of efficacy through lower target-mediated clearance. Previous studies have shown that administration of statins increases the production of free PCSK9. In the studies analyzed herein, patients who received mAb316P plus diet alone had lower baseline free PCSK9 levels and higher mAb316P blood concentrations compared with patients who received mAb316P plus atorvastatin therapy.

[0105] In patients receiving concomitant statin therapy, mAb316P administered Q2W achieved lower variation in LDL-C lowering at the end of the dosing interval as compared with Q4W dosing regimens. In Q4W dosing, patient-to-patient differences in target-mediated clearance (among other factors) appeared to contribute to differences in the duration of maximum LDL-C between Weeks 2 and 4 post dose and therefore wider differences in achieved efficacy 4 weeks after dosing. These differences were not observed when doses were administered Q2W.

Example 3A: An Anti-PCSK9 Antibody Reduces Cholesterol Concentrations of Serum Remnant Lipoprotein Fractions, Very Low Density Lipoproteins, Triglycerides, and Lipoprotein(a) [Lp(a)]

Introduction

[0106] Increased very low-density lipoproteins (VLDL) levels form part of a pattern of atherogenic dyslipidemia, which predisposes to premature atherosclerosis. Remnant lipoproteins are products of VLDL lipolysis, and include VLDL₃and intermediate-density lipoproteins (IDL, the direct precursor to LDL formation).

[0107] Lipoprotein(a) [Lp(a)] consists of apolipoprotein(a) [apo(a)] covalently bound to the apo B component of a cholesterol-rich lipoprotein which is approximately the same size as a low-density lipoprotein (LDL) particle. Lp(a) metabolism is under mostly genetic regulation, in that more than 90% of its plasma concentration is influenced by quantitative and qualitative polymorphisms at the apo(a) gene (LPA). Elevated Lp(a) levels are considered to be an independent risk factor for cardiovascular disease, with risk continuing to increase as levels rise. Although elevated Lp(a) may promote atherosclerosis through intimal deposition of cholesterol, it may also promote thrombosis due to a high homology with plasminogen, although it lacks protease activity. In patients undergoing coronary angiography, Lp(a) concentrations>30 mg/dL have been shown to be associated with an increased risk of angiographic stenosis and major coronary events. Furthermore, Lp(a) levels and genotype have been shown to be associated with aortic-valve calcification, suggesting it may play a role in causation.

[0108] The objective of this Example was to test the hypothesis that mAb316P, a fully human monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9), reduces serum levels of VLDL and lipoprotein remnants, contributing to its ability to reduce serum LDL-C and non-HDL-C, and to confirm the Lp(a) lowering activity of mAb316P in patients.

[0109] Three multicenter, double-blind, parallel-group, placebo-controlled trials were conducted in patients with primary hypercholesterolemia (Study A, n=183; Study B, n=92) or heterozygous familial hypercholesterolemia (Study C, n=77). A summary of the designs and dosing for the three trials is shown in Table 1.

[0110]

TABLE 1

Summary of Designs and Dosing for mAb316P Clinical Trials


	Study
	A	B	C

Duration	12 weeks	8 weeks	12 weeks
Patients	hypercholesterolemia	hypercholesterolemia	heterozygous familial
	(n = 183)	(n = 92)	hypercholesterolemeia
			(n = 77)
mAb316P Doses	200-300 mg Q4W	150 mg Q2W + ATV 10	150, 200, 300 mg Q4W
	50-100 mg Q2W	to 80 mg	150 mg Q2W
	150 mg Q2W	150 mg Q2W + ATV 10	(n = 16)
	(n = 31)	to 80 mg (total n = 61)
Placebo	n = 31	Placebo + ATV 10	n = 15
		to 80 mg (n = 31)
Pooled Analysis Population	mAb316P 150 mg Q2W (n = 108)	Placebo (n = 77)

[0111] In Study B, all patients received atorvastatin (ATV) 10 mg prior to randomization, which was uptitrated to ATV 80 mg at the start of randomized treatment in the placebo and one mAb316P arm.

[0112] Patients on background atorvastatin or statins+/−ezetimibe received mAb316P 50-300 mg administered subcutaneously (SC) either every 2 or 4 weeks (Q2W, Q4W), depending on the study. The mAb316P 150 mg Q2W dose was common to all three trials.

[0113] In post hoc analyses, lipoproteins were subfractionated by vertical auto profile (VAP) testing. The VAP method is a single, direct ultracentrifugation test that separates the lipoprotein fractions according to their densities in a vertical rotor, which allows high resolution of each lipoprotein class and subclass. The bottom of the tube is punctured and the cholesterol in each layer is measured with a spectrophotometer after the addition of an enzymatic cholesterol reagent. Percent changes in VLDL-C, VLDL₁₊₂-C (a measure of cholesterol in “large, buoyant” VLDL particles), triglycerides (TG), VLDL₃-C, IDL-C and total remnant lipoprotein cholesterol levels (RLP-C; VLDL₃-C+IDL-C) in patients treated with mAb316P 150 mg Q2W vs. placebo were analyzed at week 12 (Study A), week 8 (Study B) and week 6 (Study C) using ANCOVA.

[0114] In addition, baseline and on-treatment Lp(a) levels were assessed in patients from the three different Phase 2 studies receiving mAb316P 150 mg Q2W or placebo. In all Phase 2 studies Lp(a) levels were measured at the same laboratory and using the same method. Data on Lp(a) levels at baseline and end of treatment (Week 8/12 on-treatment value or the last available on-treatment value carried forward) from the modified intention-to-treat populations of the three studies were pooled, and percentage changes from baseline for mAb316P 150 mg Q2W and placebo were compared using analysis of covariance with treatment group and study as fixed effects and baseline Lp(a) as covariate. P-values associated with these exploratory analyses are provided for descriptive purposes only and were not adjusted for multiplicity. The relationship between the percentage changes from baseline in Lp(a) and LDL-C was assessed using linear regression, and the Spearman's correlation coefficient was calculated.

Results/Conclusions

[0115] In the 3 studies, reductions in TG, VLDL-C, and in the cholesterol content of remnant lipoprotein were observed with mAb316P vs. placebo. Results are summarized in Table 2 and FIGS. 7-9.

[0116]

TABLE 2

	Baseline (mg/dL)	Endpoint (mg/dL)	Percent Change	p-value (s)

VLDL	23.24 to 26.31	16.62 to 18.12	−22.33 to −27.95	0.0023 to <0.0001
VLDL₁₊₂-C	9.79 to 10.59	6.59 to 7.31	−21.87 to −31.45	0.0178 to <0.0001
VLDL₃	13.55 to 15.62	10.03 to 10.88	−21.9 to −26.66	0.0011 to <0.0001
TG	135.72 to 157.19	99.9 to 124.44	−13.07 to −21.19	0.6945 to 0.0003
IDL	15.38 to 22.06	6.79 to 8.62	−50.28 to −55.75	<0.0001
RLPC	29.34 to 37.69	16.86 to 19.5	−37.05 to −44.04	<0.0001

[0117] The entire spectrum of atherogenic lipoproteins (LDL-C, IDL-C, VLDL-C and RLP subfractions) was reduced by mAb316P, against a background of lipid lowering therapy (statins±ezetimibe), in heFH/non-FH patients. This Example therefore illustrates that mAb316P significantly reduced serum TG and VLDL-C, in addition to significant reductions in cholesterol concentrations of remnant lipoprotein fractions separable by VAP, including VLDL₃-C and IDL-C.

[0118] Baseline and on-treatment Lp(a) data were available for 102 of the 108 patients who received mAb316P 150 mg Q2W and 74 of the 77 patients who received placebo in the Pooled Analysis Population. Baseline values are shown in Table 3.

[0119]

TABLE 3

Baseline Lp(a) Levels in Patients Included in the Pooled Analysis
	Placebo	mAb316P 150 mg Q2W
	(n = 74)	(n = 102)

Lp(a) values in mg/dL
Overall Population, median	19.0 (6.0-77.0)	29.5 (8.0-70.0)
(IQR)
Range	1.5-299.0	1.5-181.0
Number of Patients Subdivided by Baseline Lp(a)
≤50 mg/dL, n (%)	49 (66.2)	68 (66.7)
>50 mg/dL, n (%)	25 (33.8)	36 (35.3)

*Patients from the mITT population with Lp(a) data available at baseline and end of treatment (Week 8/12 on-treatment value or the last available on-treatment value carried forward).

[0120] As shown in Table 3, 36 (35%) patients treated with mAb316P and 25 (33%) patients treated with placebo had baseline Lp(a) >50 mg/dL, considered as the high-risk cut-point by the EAS guidelines.

[0121] Absolute and percentage median reductions from baseline in Lp(a) are summarized in Table 4.

[0122]

TABLE 4

Lp(a) Change From Baseline
		Patients Subdivided by Baseline Lp(a)
All Patients	≤50 mg/dL	>50 mg/dL
pooled	pooled	pooled	pooled	pooled	pooled
placebo	mAb316P	placebo	mAb316P	placebo	mAb316P
treated	treated	treated	treated	treated	treated
(n = 74)	(n = 102)	(n = 49)	(n = 68)	(n = 25)	(n = 34)

Median Lp(a) Change From Baseline, mg/dL (IQR; LOCF)
−0.5	−9.0	0.0	−3.5	−5.0	−26.5
(−5.0-2.0)	(−19.0-−2.0)*	(−3.0-1.5)	(−11.5-−1.5)*	(−11.0-6.0)	(−39.0-−16.0)*
Median Lp(a) Percent Change From Baseline, (IQR; LOCF)
−0.3%	−30.3%	0.0%	−36.1%	−4.4%	−27.0%
(−16.7-11.5)	(−50.0-−19.4)*	(−16.7-16.7)	(−51.1-−17.4)*	(−9.4-7.1)	(−32.6-−19.6)*

*P < 0.0001 vs placebo.

[0123] As shown in Table 4, the median percentage reduction from baseline in Lp(a) was −30.3% with mAb316P 150 mg Q2W versus −0.3% with placebo (P<0.0001). The absolute median reductions in Lp(a) from baseline were substantially greater in patients with the higher baseline Lp(a). In summary, an analysis of data pooled from three Phase 2 trials conducted with mAb316P 150 mg Q2W demonstrated significant reductions in Lp(a) versus placebo, including in patients with baseline Lp(a)>50 mg/dL. In those patients considered at higher cardiovascular disease risk due to elevated Lp(a), the percentage reductions in Lp(a) appeared to be of similar magnitude resulting in greater absolute reductions in Lp(a).

Example 3B: An Anti-PCSK9 Antibody Reduces Apolipoprotein CII and CIII Levels in Serum

Introduction

[0124] Apoprotein (apo) CIII inhibits lipoprotein lipase (LPL)-mediated catabolism of VLDL triglycerides. Apo CII appears to have a more complex relationship with VLDL and LPL activity that may depend on baseline triglyceride levels. Apo CII is, in general, an important activator of LPL

[0125] LPL hydrolyzes the triglyceride mass of VLDL and its remnants. In this Example, the ability of an anti-PCSK9 antibody, mAb316P, to reduce VLDL-C and remnants by impacting serum levels of apoproteins CII and CIII was investigated.

[0126] Three multicenter, double-blind, parallel-group, placebo-controlled trials were conducted in patients with primary (non-familial) hypercholesterolemia (non-FH) (Study A, n=183; Study B, n=92) or heterozygous familial hypercholesterolemia (heFH) (Study C, n=77). Patients (who were receiving atorvastatin or statins+/−ezetimibe) were treated with mAb316P 50-150 mg every 2 wks (Q2W) or 150-300 mg every 4 wks (Q4W) depending on the study. The mAb316P 150 mg Q2W dose was common to all three trials. (See Example 3A, Table 1).

[0127] In post hoc analyses, apo CII and CIII concentrations were measured via immunoassay. (using reagent kits from Randox Laboratories Limited, UK [apo CII, Cat. No. LP3866; apo CIII, Cat. No. LP3865] and an Architect Ci8200 analyzer [Abbott Laboratories, IL]). The immunoassay methods were based on the reaction of a sample containing human apo CII (or apo CIII) and specific antiserum to apo CII (or CIII) to form an insoluble complex whose concentration can be measured turbidimetrically at 340 nm. Both assays were validated for analytical performance.

[0128] Percent change from baseline in apo CII and apo CIII in the placebo group was compared with patients treated with mAb316P, analyzed at week 12 (Study A), week 8 (Study B) and week 6 (Study C) using analysis of covariance. Study C had a Week 12 endpoint; however, 6-week data were used due to reduced number of patients with available stored samples at 12 weeks (n=17) compared with 6 weeks (n=75).

Results

[0129] Percent change in apo CII and CIII from baseline by treatment group for mAb316P 150 mg Q2W in Studies A, B and C are shown in Table 5. Values shown are mean (SD), except for apo CIII, where values are median (IQR). Data are from Week 12 (study A), Week 8 (study B) and Week 6 (study C). FIG. 13 shows the dose response changes in apo CII (panel A) and CIII (panel B) for study A.

[0130]

TABLE 5

		P-value		P-value
	Apo CII	versus	Apo CIII	versus
	% change	placebo	% change	placebo

Study A
Placebo	12.0		3.76
	(33.0)		(−5.5 to 27.6)
mAb316P	−21.4	<0.00001	−24.7	<0.00001
150 mg	(26.5)		(−28.4 to −2.9)
Q2W
Study B
Placebo	−10.6		−7.0
	(30.2)		(29.8 to 7.3)
mAb316P	−10.0	0.98	−4.9	0.4426
150 mg Q2W +	(22.7)		(−24.4 to 1.0)
atorvastatin
10 mg
mAb316P	−29.3	0.0067	−22.9	0.0165
150 mg Q2W +	(19.29)		(−28 to −14.0)
atorvastatin
80 mg
Study C
Placebo	1.6		−3.3
	(15.5)		(−15.3 to 5.6)
mAb316P	−9.4	0.0794	−20.2	0.019
150 mg	(28.1)		(−29.0 to 2.5)
Q2W

[0131] mAb316P reduced apo CII and CIII at all doses, but a clear dose response was observed (Table 5, FIG. 13). In all three studies, mAb316P reduced apo CII in patients from baseline (Table 5). The mean reductions from baseline at Week 12 (study A), Week 8 (study B) and Week 6 (study C) were 21.4% (P<0.00001), 29.3% (P=0.0067) and 9.4% (P=0.08), respectively (P-values compared with placebo). Apo CIII was reduced by 24.7% (P<0.00001), 22.9% (P=0.017) and 20.2% (P=0.019), for studies A, B and C, respectively (P-values compared with placebo).

Conclusions

[0132] Therapy with anti-PCSK9 antibody mAb316P was associated with significant reductions in serum apo CII and CIII. There was a nearly 1:1 reduction in both apo CII and CIII in patients with non-FH. In patients with heFH, apo CIII decreased approximately two-fold more than apo CII. The reductions in apo CII and CIII may be a manifestation of either increased clearance or reduced production/secretion of VLDL particles, known carriers of these apoproteins.

Example 4: An Anti-PCSK9 Antibody Reduces Cholesterol Concentrations of all Serum Low-Density Lipoprotein Fractions

Introduction

[0133] Low-density lipoprotein cholesterol (LDL-C) is composed of a continuum of LDL particles of different densities and states of lipidation. Analysis of effects of lipid-modifying therapies on LDL particle composition may aid understanding of treatment mode-of-action. The purpose of this Example was to test the hypothesis that mAb316P, a fully human monoclonal antibody to proprotein convertase subtilisin/kexin 9 (PCSK9), reduces LDL-C by decreasing multiple LDL fractions.

[0134] Three multicenter, double-blind, parallel-group, placebo-controlled trials were conducted in patients with primary hypercholesterolemia (Study A, n=183; Study B, n=92) or heterozygous familial hypercholesterolemia (Study C, n=77). Patients (who were receiving atorvastatin or statins+/−ezetimibe) were treated with mAb316P 50-150 mg every 2 wks (Q2W) or 150-300 mg every 4 wks (Q4W) depending on the study. The mAb316P 150 mg Q2W dose was common to all three trials. (See Example 3A, Table 1).

[0135] In post hoc analyses, lipoproteins were subfractionated by vertical auto profile (VAP) testing. Percent change in LDL₁-C (“large buoyant” LDL), LDL₂-C, LDL₃-C, and LDL₄-C (“small, dense” LDL) levels in patients receiving mAb316P 150 mg Q2W vs. placebo from baseline to week 12 for Study A, week 8 for Study B, and week 6 for Study C were assessed using ANCOVA. The LDL₃-C and LDL₄-C fractions were analyzed individually and in a pooled analysis. This was done because LDL₄-C typically exists at substantially lower concentrations than LDL₃₋₄-C. There was much more substantial variation in percent reductions in LDL₄-C. The sum of LDL₃₊₄-C represents a sum of the two smallest and densest LDL-C fractions.

Results/Conclusions

[0136] Significant reductions from baseline in cholesterol content of all LDL subfractions separable by VAP were observed in patients receiving mAb316P 150 mg Q2W in the 3 studies, vs. placebo. Results are summarized in Table 6 and FIGS. 10-12.

[0137]

TABLE 6

	Baseline (mg/dL)	Endpoint (mg/dL)	Percent Change	p-value

LDL₁	16.18 to 25.92	3.56 to 6.81	−68.87 to −77.84	<0.0001
LDL₂	20.29 to 31.46	3.04 to 7.84	−77.85 to −84.17	<0.0001
LDL₃₄	46.33 to 49.16	14.9 to 22.29	−48.77 to −68.49	<0.0001

[0138] This Example therefore illustrates that therapy with a monoclonal antibody directed against PCSK9 (mAb316P) significantly reduced cholesterol concentrations in LDL fractions separable by VAP. The previously demonstrated LDL-C reductions with mAb316P were confirmed across the spectrum of LDL-C sub-fractions.

Example 5: Effects of an Anti-PCSK9 Antibody on Lipoprotein Particle Concentrations

Background

[0139] The cholesterol content of low-density lipoprotein particles (LDL-P) and high-density lipoprotein particles (HDL-P) can vary greatly among individuals. For example, one individual may have larger, cholesterol-rich LDL-P, and another will have smaller, cholesterol-poor LDL-P. Therefore measurements of serum levels of low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) often do not correlate with circulating LDL-P and HDL-P number.

[0140] Epidemiological studies have demonstrated that atherosclerotic cardiovascular disease risk tracks with both LDL-C and LDL-P. However, in patient populations where these measures are discordant (e.g., patients with diabetes or metabolic syndrome), risk has been shown to track more consistently with LDL-P than LDL-C. Consequently, multiple expert panels and consensus statements have advocated the adjunctive use of LDL-P as a target of therapy in the management of high-risk patients.

[0141] Nuclear magnetic resonance (NMR) technology can accurately measure the number of circulating lipoprotein particles to identify patients with discordantly high LDL-P levels that require intensification of therapy.

[0142] The anti-PCSK9 antibody mAb316P, has been shown to reduce LDL-C by up to 72.4% in patients on stable doses of atorvastatin over 12 weeks with similar rates of adverse events between placebo and mAb316P-treatment groups. mAb316P reduced apolipoprotein B by up to 56% proportionally with the changes in LDL-C. The effect of mAb316P on lipoprotein particle numbers in hypercholesterolemic patients has heretofore not been reported.

[0143] The present Example sets forth an evaluation of the effects of mAb316P on the concentration and size of lipoprotein particles.

Methods

[0144] A sub-study of a randomized double-blind Phase II trial was carried out with respect to patients with LDL-C ≥100 mg/dL who received placebo (n=31) or mAb316P 150 mg administered subcutaneously (SC) every 2 weeks (Q2W) (n=28) on top of stable daily atorvastatin (10, 20 or 40 mg daily). Lipid and lipoprotein tests were performed using samples collected after a 12-hour overnight fast. Lipoprotein particle profiles were measured by NMR spectroscopy using the LipoProfile-3 algorithm at LipoScience, Inc. (Raleigh, N.C.). LDL-P and HDL-P subclasses were quantified from the amplitudes of their spectroscopically distinct lipid methyl group NMR signals, and weighted-average LDL and HDL sizes were derived from the sum of the diameter of each subclass multiplied by its relative mass percentage based on the amplitude of its methyl NMR signal.

[0145] Diameter range estimates for the subclasses were as follows:

[0146] VLDL-P: small VLDL-P=29 to 42 nm; medium VLDL-P=42 to 60 nm; large VLDL-P>60 nm;

[0147] LDL-P: small LDL-P=18 to 20.5 nm; large LDL-P=20.5 to 23 nm; intermediate-density lipoprotein particles (IDL-P)=23 to 29 nm;

[0148] HDL-P: small HDL-P=7.3 to 8.2 nm; medium HDL-P=8.2 to 9.4 nm; and large HDL-P=9.4 to 14 nm.

[0149] Total VLDL-P, LDL-P, and HDL-P equal the sum of the particle number concentrations of the VLDL, LDL, and HDL subclasses, respectively. Endpoints for the analysis were percentage change in the concentration of LDL-P, VLDL-P and HDL-P from baseline to Week 12.

[0150] Any variables that were not normally distributed were transformed for all statistical tests, but the untransformed variables are presented in the tables herein. Mean (standard deviation [SD]) are reported for continuous normally distributed variables, while median (interquartile range [IQR]) are reported for any non-normally distributed variables. Count and percentage are reported for categorical variables. To determine if the treatment group was significantly different than placebo, Fisher's exact tests were performed and the associated P-values are reported. To determine if each of the treatment groups were significantly different than placebo, t-tests were performed and the associated P-values are reported. To determine if there was a significant difference in percent change between baseline and Week 12 for the placebo compared to the treatment groups analysis of covariances were performed with the baseline value as a covariate.

Results

[0151] Table 7 shows lipoprotein particle concentrations before and after mAb316P 150 mg SC Q2W compared to placebo.

[0152]

TABLE 7

Lipoprotein particle concentrations (nmol/L) for
placebo (n = 31) and mAb316P 150 mg Q2W (n = 28).
Mean (sd) or median (Q1:Q3)
[proportion of total]	Baseline	Week 12	% change

		PLACEBO
LDL	Total LDL	1422.5	(321.3)	1383.8	(327.9)	−1.0%
	Intermediate	110	(51:166.5)	57	(24.5:144.5)	−15.0%
	density
	lipoprotein
	Large LDL	546.6	(205.3)	431.8	(217.4)	−21.8%
	Small LDL	755.3	(304.9)	847.6	(375.1)	17.8%
VLDL +	Total VLDL +	61.9	(47.8:95.6)	83.9	(45:102.2)	33.4%
chylomicron	chylomicron
	Large VLDL +	3.5	(2.1:8.5)	4.3	(1.8:9.4)	14.3%
	chylomicron
	Medium VLDL	19.3	(13.1:33.9)	33.1	(13.1:51.9)	24.0%
	Small VLDL	35.3	(28.2:47.8)	37.3	(23.4:56.3)	21.4%
HDL	Total HDL	32.9	(6.4)	33.2	(7.4)	1.4%
	Large HDL	3.8	(2.0)	3.9	(2.2)	6.99%
	Medium HDL	9.2	(5.9:14.4)	8	(5.4:10.2)	−13.9%
	Small HDL	18.8	(5.3)	21.3	(5.8)	18.4%
		mAb316P 150 mg Q2W
LDL	Total LDL	1320	(304.0)	475.4	(167.3)†	−63.3%†
	Intermediate	84.5	(33:115)	37	(12:66)*	−52.8%
	density
	lipoprotein
	Large LDL	532.2	(212.9)	152.4	(107.6)†	−71.3%
	Small LDL	666.5	(333.8)	279.9	(191.0)†	−54.0%
VLDL +	Total VLDL +	71.5	(36.9:94.1)	42.0	(30.5:54.1)†	−36.4%†
chylomicron	chylomicron
	Large VLDL +	3.6	(1.8:8.5)	3.1	(1.7:6.9)	5.37%
	chylomicron
	Medium VLDL	18.3	(10.7:50)	14.4	(8.2:26.9)†	−38.92%
	Small VLDL	35.7	(25:49.5)	21.4	(19.9:26.7)*	−33.4%
HDL	Total HDL	32.6	(6.3)	36.1	(6.5)*	11.2%*
	Large HDL	4.8	(3.1)	6.1	(3.5)*	44.6%
	Medium HDL	7.8	(5.6:10.7)	9.8	(6.6:11.3)	17.65%
	Small HDL	19.4	(4.1)	20.0	(5.7)*	2.8%

*P < 0.05;
†P < 0.001 vs. placebo

[0153] mAb316P reduced mean LDL-P by 63% vs 1% for placebo (P<0.0001) and median VLDL-P by 36% vs an increase of 33% for placebo (P<0.0001). HDL-P levels increased 11% for mAb316P vs 1% for placebo (P<0.05). Changes in all particle subclasses were directionally similar.

Conclusion

[0154] mAb316P significantly reduced LDL-P and other lipoprotein particles in a manner similar to its previously reported effect on LDL-C and apolipoprotein B.

Example 6: Effects of an Anti-PCSK9 Antibody on Lipoprotein Subfractions as Determined by Ion Mobility

Background

[0155] mAb316P (also known as Alirocumab) has demonstrated significant reductions in low-density lipoprotein cholesterol (LDL-C) in Phase 2 clinical trials. LDL-C tracks closely with cardiovascular disease (CVD) risk and subfractions of LDL, defined by differences in particle size and density, have also been associated with varying degrees of CVD risk. Analysis of lipoprotein subfractions may provide further insight into CVD risk evaluation and the effects of lipid-lowering treatments seen in individual patients.

Methods

[0156] A Phase 2 randomized, double-blind, clinical trial was conducted in patients with hypercholesterolemia and LDL-C levels≥100 mg/dL, in which 31 patients received placebo and 27 patients received alirocumab 150 mg every 2 weeks (Q2W) via a 1-mL subcutaneous auto-injection in addition to stable atorvastatin (10-40 mg daily). In the present sub-study, lipoprotein subfractions were determined at baseline and at Week 12 using ion mobility.

Results

[0157] Changes in lipoprotein subfractions and lipid parameters from baseline to Week 12 are set forth in Tables 8A (placebo-treated) and 8B (mAb316P-treated).

[0158]

TABLE 8A

Placebo
			Percent
	Baseline	Week 12	Change

Lipoprotein
subfractions
VLDL + IDL +	1648.44	(453.5)	1728.88	(434.58)	8.25
Total LDL
VLDL (large +	134.97	(109.01 to 152.85)	140.48	(106.18 to 193.49)	6.64
intermediate +
small)
IDL (IDL 1 + 2)	314.28	(282.74 to 407.95)	303.35	(277.99 to 376.17)	−3.3
Total LDL	1172.99	(362.85)	1233.76	(331.13)	8.8
Large LDL	448.23	(173.52)	419.36	(160.98)	−0.26
(LDL 1 + 2a)
Medium LDL	233.2	(105.34)	228.92	(88.12)	5.07
(LDL 2b)
Small LDL	195.17	(85.53)	225.98	(105.1)	24.39
(LDL 3a)
Very Small LDL	296.4	(91.75)	359.49	(136.92)	24.61
(LDL 4a + 4b +
4c + 3b)
HDL (HDL 2b;	23532.48	(5392.57)	24400.97	(5798.21)	0.06
HDL3 + 2a)
Lipid parameters
LDL-C, mg/dL	130.2	(27.3)	120.5	(27.0)	−5.1
HDL-C, mg/dL	49.0	(10.3)	48.9	(13.2)	−1.0
TG, mg/dL	124.0	(92.0 to 187.5)	127.0	(98.0 to 197.0)	9.7
Apo-B, mg/dL	108.3	(19.3)	109.2	(27.0)	2.2
Apo-A1, g/L	1.4	(1.3 to 1.6)	1.4	(1.3 to 1.7)	0.0
Lp(a), g/L	0.2	(0.1 to 0.9)	0.2	(0.07 to 0.85)	0.0

[0159]

TABLE 8B

mAb316P 150 mg Q2W
			Percent
			Change
	Baseline	Week 12	(p-value)

Lipoprotein subfractions
VLDL + IDL + Total LDL	1542.82	(435.5)	767.78	(212.39)	−48.68
			(<0.0001)
VLDL (large +	138.17	(96.41 to 167.8)	77.2	(51.81 to 95.8)	−51.37
intermediate + small)			(<0.0001)
IDL (IDL 1 + 2)	309.64	(268.32 to 363.95)	155.19	(134.05 to 194.5)	−52.29
			(<0.0001)
Total LDL	1078.28	(347.61)	529.35	(171)	−49.84
			(<0.0001)
Large LDL (LDL 1 + 2a)	421.08	(130.03)	152.66	(53.4)	−62.66
			(<0.0001)
Medium LDL (LDL 2b)	200.86	(91.4)	78.67	(40.76)	−58.69
			(<0.0001)
Small LDL (LDL 3a)	172.02	(104.89)	79.24	(38.36)	−48.56
			(<0.0001)
Very Small LDL (LDL	284.31	(101.87)	218.77	(55.66)	−17.91
4a + 4b + 4c + 3b)			(<0.0001)
HDL (HDL 2b;	23480.25	(5281.63)	21888.87	(4515.15)	−0.05
HDL3 + 2a)			(0.0339)
Lipid parameters
LDL-C, mg/dL	123.9	(26.7)	34.2	(15.6)	−72.4
			(<0.0001)*
HDL-C, mg/dL	53.3	(16.1)	55.1	(14.8)	5.5
					(0.570)‡
TG, mg/dL	140.5	(92.5 to 177.5)	99.0	(79.0 to 139.0)	−18.9
			(0.0006)‡
Apo-B, mg/dL	101.6	(26.6)	44.1	(14.1)	−56.1
			(<0.0001)‡
Apo-A1, g/L	1.5	(1.3 to 1.7)	1.6	(1.4 to 1.7)	1.4
			(0.1524)‡
Lp(a), g/L	0.3	(0.1 to 0.6)	0.1	(0.05 to 0.41)	−28.6
			(<0.0001)‡

*Statistically significant p-value according to the hierarchical procedure.
‡P-values are not adjusted for multiplicity and are for descriptive purposes only.

[0160] Tables 8A and 8B illustrate changes in lipoprotein subfractions and lipid parameters in placebo and mAb316P 150 mg Q2W groups, respectively, from baseline to Week 12. Compared with placebo, mAb316P reduced very low-density lipoprotein (VLDL)+intermediate-density lipoprotein (IDL)+total LDL by 48.7% (p<0.0001), VLDL by 51.4% (p<0.0001), IDL by 52.3% (p<0.0001) and total LDL by 49.8% (p<0.0001); changes in other subfractions were directionally similar. No significant change was noted for HDL. There was a highly significant difference in percent change reduction in very small LDL versus the other LDL fractions (p<0.0001).

Conclusions

[0161] As determined by ion mobility, mAb316P significantly reduced LDL subfractions when added to stable atorvastatin therapy, similar to its previously reported effect on LDL-C.

[0162] The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and the accompanying figures. Such modifications are intended to fall within the scope of the appended claims.

Claims

What is claimed is:

1. A method for reducing in a patient the serum concentration of IDL-C; the method comprising selecting a patient with elevated serum IDL-C, and administering to the patient a pharmaceutical composition comprising a PCSK9 inhibitor;

wherein the patient is otherwise healthy except for exhibiting elevated serum IDL-C; and

wherein the PCSK9 inhibitor is an antibody or antigen-binding fragment of an antibody that specifically binds PCSK9 and comprises the heavy and light chain CDRs of a HCVR/LCVR amino acid sequence pair selected from the group consisting of SEQ ID Nos: 90/92 and 218/226.

2. The method of claim 1, wherein the serum IDL-C is reduced in the patient by at least about 50% to about 56% from baseline following administration of the pharmaceutical composition.

3. The method of claim 1, wherein the pharmaceutical composition comprises 20 mg to 200 mg of the PCSK9 inhibitor.

4. The method of claim 3, wherein the pharmaceutical composition comprises 75 mg or 150 mg of the PCSK9 inhibitor.

5. The method of claim 1, wherein the antibody or antigen-binding fragment thereof comprises heavy and light chain CDR amino acid sequences having SEQ ID NOs: 220, 222, 224, 228, 230 and 232.

6. The method of claim 5, wherein the antibody or antigen-binding fragment thereof comprises an HCVR having the amino acid sequence of SEQ ID NO:218 and an LCVR having the amino acid sequence of SEQ ID NO:226.

7. The method of claim 1, wherein the antibody or antigen-binding fragment thereof comprises heavy and light chain CDR amino acid sequences having SEQ ID NOs: 76, 78, 80, 84, 86 and 88.

8. The method of claim 7, wherein the antibody or antigen-binding fragment thereof comprises an HCVR having the amino acid sequence of SEQ ID NO:90 and an LCVR having the amino acid sequence of SEQ ID NO:92.

9. The method of claim 1, wherein the patient is on a therapeutic statin regimen at the time of or just prior to administration of the pharmaceutical composition.

10. The method of claim 9, wherein the therapeutic statin regimen comprises a statin selected from the group consisting of cerivastatin, atorvastatin, simvastatin, pitavastatin, rosuvastatin, fluvastatin, lovastatin and pravastatin.

11. The method of claim 10, wherein the statin is atorvastatin.

12. The method of claim 1, wherein the patient is not on a therapeutic statin regimen at the time of administration of the pharmaceutical composition.

Patent Citations (182)

Patent	Date	Inventor	Cited By
US5260440(A)	1993-11-01	Hirai	Applicant
US5273995(A)	1993-12-01	Roth	Applicant
US5399670(A)	1995-03-01	Bhattacharya	Applicant
US5851999(A)	1998-12-01	Ulrich	Applicant
US5939598(A)	1999-08-01	Kucherlapati	Applicant
US6011003(A)	2000-01-01	Charmock-Jones	Applicant
US6171586(B1)	2001-01-01	Lam	Applicant
US6267958(B1)	2001-07-01	Andya	Applicant
US6270993(B1)	2001-08-01	Shibuya	Applicant
US6596541(B2)	2003-07-01	Murphy	Applicant
US6629949(B1)	2003-10-01	Douglas	Applicant
US6659982(B2)	2003-12-01	Douglas	Applicant
US6875432(B2)	2005-04-01	Liu	Applicant
US6946548(B2)	2005-09-01	Sarkar	Applicant
US7001892(B1)	2006-02-01	Chmielweski	Applicant
US7029895(B2)	2006-04-01	Glucksmann	Applicant
US7060268(B2)	2006-06-01	Andya	Applicant
US7129338(B1)	2006-10-01	Ota	Applicant
US7300754(B2)	2007-11-01	Fadel	Applicant
US7482147(B2)	2009-01-01	Glucksmann	Applicant
US7572618(B2)	2009-08-01	Mintier	Applicant
US7608693(B2)	2009-10-01	Martin	Applicant
US7754208(B2)	2010-07-01	Ledbetter	Applicant
US8030457(B2)	2011-10-01	Jackson	Applicant
US8062640(B2)	2011-11-01	Sleeman	Applicant
US8080243(B2)	2011-12-01	Liang	Applicant
US8092803(B2)	2012-01-01	Furfine	Applicant
US8168762(B2)	2012-05-01	Jackson	Applicant
US8188233(B2)	2012-05-01	Condra	Applicant
US8188234(B2)	2012-05-01	Condra	Applicant
US8357371(B2)	2013-01-01	Sleeman	Examiner
US8501184(B2)	2013-08-01	Sleeman	Applicant
US8795669(B2)	2014-08-01	Dix	Applicant
US8829165(B2)	2014-09-01	Jackson	Applicant
US8883157(B1)	2014-11-01	Clube	Applicant
US9034332(B1)	2015-05-01	Clube	Applicant
US9127068(B2)	2015-09-01	Okamoto	Applicant
US9193801(B2)	2015-11-01	Walsh	Applicant
US9358287(B2)	2016-06-01	Harp	Applicant
US9540449(B2)	2017-01-01	Yancopoulos	Applicant
US9550837(B2)	2017-01-01	Sleeman	Examiner
US2003/0092606(A1)	2003-05-01	L'Italien	Applicant
US2003/0113316(A1)	2003-06-01	Kaisheva	Applicant
US2003/0118592(A1)	2003-06-01	Ledbetter	Applicant
US2003/0133939(A1)	2003-07-01	Ledbetter	Applicant
US2004/0101920(A1)	2004-05-01	Radziejewski	Applicant
US2004/0197324(A1)	2004-10-01	Liu	Applicant
US2005/0281831(A1)	2005-12-01	Davis-Smyth	Applicant
US2006/0147945(A1)	2006-07-01	Edmonds	Applicant
US2007/0082345(A1)	2007-04-01	Ota	Applicant
US2007/0224663(A1)	2007-09-01	Rosen	Applicant
US2008/0008697(A1)	2008-01-01	Mintier	Applicant
US2009/0142352(A1)	2009-06-01	Jackson	Applicant
US2009/0232795(A1)	2009-09-01	Condra	Applicant
US2009/0246192(A1)	2009-10-01	Condra	Applicant
US2009/0269350(A1)	2009-10-01	Glucksmann	Applicant
US2009/0318536(A1)	2009-12-01	Freier	Applicant
US2009/0326202(A1)	2009-12-01	Jackson	Applicant
US2010/0040610(A1)	2010-02-01	Sitlani	Applicant
US2010/0040611(A1)	2010-02-01	Sparrow	Applicant
US2010/0041102(A1)	2010-02-01	Sitlani	Applicant
US2010/0068199(A1)	2010-03-01	Liang	Applicant
US2010/0136028(A1)	2010-06-01	Sparrow	Applicant
US2010/0150937(A1)	2010-06-01	Sparrow	Applicant
US2010/0166768(A1)	2010-07-01	Sleeman	Applicant
US2010/0233177(A1)	2010-09-01	Yowe	Applicant
US2011/0027287(A1)	2011-02-01	Jackson	Applicant
US2011/0033465(A1)	2011-02-01	Hedrick	Applicant
US2011/0065902(A1)	2011-03-01	Sleeman	Applicant
US2011/0098450(A1)	2011-04-01	Igawa	Applicant
US2011/0111406(A1)	2011-05-01	Igawa	Applicant
US2011/0142849(A1)	2011-06-01	Rue	Applicant
US2011/0171241(A1)	2011-07-01	Dix	Applicant
US2011/0229489(A1)	2011-09-01	Pons	Applicant
US2011/0256148(A1)	2011-10-01	Sleeman	Examiner
US2012/0014951(A1)	2012-01-01	Liang	Applicant
US2012/0015435(A1)	2012-01-01	Liange	Applicant
US2012/0020975(A1)	2012-01-01	Jackson	Applicant
US2012/0027765(A1)	2012-02-01	Jackson	Applicant
US2012/0076799(A1)	2012-03-01	Sparrow	Applicant
US2012/0077964(A1)	2012-03-01	Sparrow	Applicant
US2012/0082679(A1)	2012-04-01	Sparrow	Applicant
US2012/0082680(A1)	2012-04-01	Sitlani	Applicant
US2012/0093818(A1)	2012-04-01	Jackson	Applicant
US2012/0097565(A1)	2012-04-01	Dix	Applicant
US2012/0195910(A1)	2012-08-01	Wu	Applicant
US2012/0213794(A1)	2012-08-01	Luo	Applicant
US2012/0213797(A1)	2012-08-01	Jackson	Applicant
US2012/0219558(A1)	2012-08-01	Ni	Applicant
US2012/0231005(A1)	2012-09-01	Luo	Applicant
US2012/0251544(A1)	2012-10-01	Jackson	Applicant
US2013/0011866(A1)	2013-01-01	Igawa	Applicant
US2013/0064825(A1)	2013-03-01	Chan	Applicant
US2013/0064834(A1)	2013-03-01	Sleeman	Applicant
US2013/0085266(A1)	2013-04-01	Sleeman	Applicant
US2013/0243784(A1)	2013-09-01	Swergold	Applicant
US2014/0004122(A1)	2014-01-01	Chan	Applicant
US2014/0099312(A1)	2014-04-01	Sleeman	Applicant
US2014/0161821(A1)	2014-06-01	Udata	Applicant
US2014/0356370(A1)	2014-12-01	Swergold	Applicant
US2015/0140002(A1)	2015-05-01	Baccara-Dinet	Applicant
US2015/0152191(A1)	2015-06-01	Baccara-Dinet	Applicant
US2015/0231236(A1)	2015-08-01	Pordy	Applicant
US2015/0283236(A1)	2015-10-01	Baccara-Dinet	Applicant
US2015/0284473(A1)	2015-10-01	Bessac	Applicant
US2016/0032015(A1)	2016-02-01	Walsh et al.	Applicant
US2016/0152734(A1)	2016-02-01	Udata	Applicant
US2017/0049886(A1)	2017-02-01	Pordy	Applicant
US2017/0096496(A1)	2017-04-01	Sleeman	Applicant
US2017/0296657(A1)	2017-10-01	Sleeman et al.	Applicant
US2018/0044436(A1)	2018-02-01	Walsh et al.	Applicant
CN101489565	2009-07-01		Applicant
EP409281	1991-01-01		Applicant
EP521471	1993-01-01		Applicant
EP1067182	2001-01-01		Applicant
EP1514933	2005-03-01		Applicant
EP1317537	2006-12-01		Applicant
EP1618212	2007-11-01		Applicant
EP2703008	2012-08-01		Applicant
EP2703009	2012-08-01		Applicant
EP2706070	2014-03-01		Applicant
WO1993/000807	1993-01-01		Applicant
WO97/035620	1997-10-01		Applicant
WO98/22136	1998-05-01		Applicant
WO99/38495	1999-08-01		Applicant
WO1/57081	2001-08-01		Applicant
WO2001/092340	2001-12-01		Applicant
WO2004/055164	2004-07-01		Applicant
WO2004/097047	2004-11-01		Applicant
WO2005/047331	2005-05-01		Applicant
WO2005103081	2005-11-01		Applicant
WO2007/143315	2007-12-01		Applicant
WO2007/149334	2007-12-01		Applicant
WO2008/054606	2008-05-01		Applicant
WO2008/057457	2008-05-01		Applicant
WO2008/057458	2008-05-01		Applicant
WO2008/057459	2008-05-01		Applicant
WO2008/063382	2008-05-01		Applicant
WO2008066776(A2)	2008-06-01		Applicant
WO2008/073300	2008-06-01		Applicant
WO2008/125623	2008-10-01		Applicant
WO2008138536(A2)	2008-11-01		Applicant
WO2008/133647	2008-11-01		Applicant
WO2009/026558	2009-02-01		Applicant
WO2009/042765	2009-04-01		Applicant
WO2009/055783	2009-04-01		Applicant
WO2009/100297	2009-08-01		Applicant
WO2009/100318	2009-08-01		Applicant
WO2010/029513	2010-03-01		Applicant
WO2010/032220	2010-03-01		Applicant
WO2010/077854	2010-07-01		Applicant
WO2010/102241	2010-09-01		Applicant
WO2010/148337	2010-12-01		Applicant
WO2011/028938	2011-03-01		Applicant
WO2011/039578	2011-04-01		Applicant
WO2011/053759	2011-05-01		Applicant
WO2011/061712	2011-05-01		Applicant
WO2011/072263	2011-06-01		Applicant
WO2011/111007	2011-09-01		Applicant
WO2012/054438	2012-04-01		Applicant
WO2012/064792	2012-05-01		Applicant
WO2012/101251	2012-08-01		Applicant
WO2012/101252	2012-08-01		Applicant
WO2012/101253	2012-08-01		Applicant
WO2012/109530	2012-08-01		Applicant
WO2012/146776	2012-11-01		Applicant
WO2012/154999	2012-11-01		Applicant
WO2012/154999	2012-11-01		Applicant
WO2013/039958	2013-03-01		Applicant
WO2013/039969	2013-03-01		Applicant
WO2013158984	2013-10-01		Applicant
WO2013/166448	2013-11-01		Applicant
WO2014/194111	2014-12-01		Applicant
WO2014/197752	2014-12-01		Applicant
WO2011/117401	2015-03-01		Applicant
WO2015/054619	2015-04-01		Applicant
WO2015/073494	2015-05-01		Applicant
WO2015/123423	2015-08-01		Applicant
WO2015/140079	2015-09-01		Applicant
WO2015/142668	2015-09-01		Applicant
WO2016/011256	2016-01-01		Applicant
WO2016/011260	2016-01-01		Applicant

Non-Patent Literature (276)

Shoji et al. (J Am Soc Nephrol 1998 9:1277-1284).Examiner
Pfizer: ‘Safety and Tolerability of Multiple Doses of PF-04950615 (RN316) In Subjects With Hypercholesterolemia.’ Nov. 3, 2012, XP002682100. Retrieved from the Internet: URL:http://clinicaltrials.gov/ct2/show?term=rn316&rank=2.Applicant
Pearson, William R., ‘Using the FASTA program to search protein and DNA sequence databases.’ Computer Analysis of Sequence Data. 1994, pp. 307-331.Applicant
Powell et al., ‘Compendium of Excipients for Parenteral Formulations PDA.’ Journal of Pharmaceutical Science and Technology. 1998, vol. 52, No. 5, pp. 238-311.Applicant
Qui et al., ‘Small antibody mimetics comprising two complementarity-determining regions and a framework region for tumor targeting.’ Nature Biotechnology. 2007, vol. 25, No. 8, pp. 921-929.Applicant
Reddy et al., ‘Elimination of Fc receptor-dependent effector functions of a modified IgG4 monoclonal antibody to human CD4.’ The Journal of Immunology. 2000, vol. 164, No. 4, pp. 1925-1933.Applicant
Reineke, Ulrich, ‘Antibody epitope mapping using arrays of synthetic peptides.’ Antibody Engineering. Humana Press. 2004, pp. 443-463.Applicant
Sefton, Michael V., ‘Implantable Pumps.’ Critical Reviews in Biomedical Engineering. 1986, vol. 14, No. 3, pp. 201-240.Applicant
Seidah et al., ‘The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation.’ PNAS. 2003,100(3):928-933.Applicant
Shields et al., ‘Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcγRIII and antibody-dependent cellular toxicity.’ Journal of Biological Chemistry. 2002, vol. 277, No. 30, pp. 26733-26740.Applicant
Soutar, Anne, ‘Unexpected Roles for PCSK9 in Lipid Metabolism.’ Current Opinion in Lipidology. 2011, vol. 22, pp. 192-196.Applicant
Tiwari et al., ‘Statins therapy: a review on conventional and novel formulation approaches.’ Journal of Pharmacy and Pharmacology. 2011, vol. 63, No. 8, pp. 983-998.Applicant
Tutt et al., ‘Trispecific F (ab′) 3 derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells.’ The Journal of Immunology. 1991, vol. 147, No. 1, pp. 60-69.Applicant
Vajdos et al., ‘Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagenesis.’ Journal of Molecular Biology. 2002, vol. 320, No. 2, pp. 415-428.Applicant
Ward et al., ‘Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli.’ Nature. 1989, vol. 341, No. 6242, pp. 544-546.Applicant
Written Opinion of the International Searching Authority for International Application No. PCT/EP2012/051320, dated Jul. 30, 2013 (16 pages).Applicant
Wu et al., ‘Receptor-mediated in vitro gene transformation by a soluble DNA carrier system.’ Journal of Biological Chemistry. 1987, vol. 262, No. 10, pp. 4429-4432.Applicant
Holliger et al., ‘Diabodies: small bivalent and bispecific antibody fragments.’ Proceedings of the National Academy of Sciences. 1993, vol. 90,No. 14, pp. 6444-6448.Applicant
Huston et al. ‘Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli.’ Proceedings of the National Academy of Sciences. 1988, vol. 85, No. 16, pp. 5879.Applicant
International Search Report for International Application No. PCT/EP2012/051320, dated Sep. 21, 2012 (9 pages).Applicant
Langer et al., ‘New methods of drug delivery.’ Science. 1990, vol. 249, No. 4976, pp. 1527-1533.Applicant
Langer et al., ‘Medical Applications of Controlled Release.’ CRC Press, Boca Raton, Florida. 1974, pp. 115-138.Applicant
Leuenberger et al., ‘A Multilingual Glossary of Biotechnological Terms.’ Recueil des Travaux Chimiques des Pays Bas. 1996, vol. 115, No. 7, pp. 382.Applicant
Padlan et al., ‘Identification of specificity-determining residues in antibodies.’ The FASEB Journal. 1995, vol. 9, No. 1, pp. 133-139.Applicant
Almagro et al., ‘Humanization of antibodies.’ Frontiers in Bioscience. 2008, vol. 13, pp. 1619-1633.Applicant
Altschul et al., ‘Basic local alignment search tool.’ Journal of Molecular Biology. 1990, vol. 215, No. 3, pp. 403-410.Applicant
Altschul et al., ‘Gapped BLAST and PSI-BLAST: a new generation of protein database search programs.’ Nucleic Acids Research. 1997, vol. 25, No. 17, pp. 3389-3402.Applicant
Amgen: ‘Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 145 in Subjects With Hyperlipidemia on Stable Doses of a Statin’. May 27, 2010, XP002682099. Retrieved from the Internet: URL:http://clinicaltrials.gov/ct2/show/nct01133522?term=amg+145&rank=2 Accessed on Aug. 6, 2014.Applicant
Angal et al., ‘A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody.’ Molecular Immunology. 1993, vol. 30, No. 1, pp. 105-108.Applicant
Bird et al., ‘Single-chain antigen-binding proteins.’ Science. 1988, vol. 242, No. 4877, pp. 423-426.Applicant
Heap et al., ‘Analysis of a 17-amino acid residue, virus-neutralizing microantibody.’ Journal of General Virology. 2005, vol. 86, No. 6, pp. 1791-1800.Applicant
Colhoun, et al., (2014) BMC Cardiovascular Disorders, Biomed Central 14(1):121, “Efficacy and safety of alirocumab, a fully human PCSK0 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the Odyssey Combo I and II trials”.Applicant
Kastelein et al., (2014) Cardiovascular Drugs and Therapy 28(3):281-289, “Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia not Adequately Controlled with Current Lipid-Lowering Therapy: Design and Rationale of the Odyssey FH Studies”.Applicant
Robinson et al., (2014) Clinical Cardiology 37(10):597-604, “Efficacy and Safety of Alirocumab as Add-on Therapy in High-Cardiovascular-Risk Patients with Hypercholesterolemia Not Adequately Controlled with Atorvastatin (20 or 40 mg) or Rosuvastatin (10 or 20 mg): Design and Rationale of the Odyssey Options Studies”.Applicant
International Search Report dated Aug. 19, 2015 for International Application No. PCT/US2015/015633.Applicant
Anthem (Sep. 21, 2015) “Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibitors,” Policy No. DRUG.00078. American Medical Association. Accessible on the Internet at URL: https://www.anthem.com/ca/medicalpolicies/policies/mp_pw_c182635.htm. [Last Accessed Apr. 27, 2016].Applicant
Defesche et al. (Jun. 2-5, 2013) “Natural history of autosomal dominant hypercholesterolemia caused by gain-of-function mutations in proprotein convertase subtilisin/kexin type 9 (PCSK9) (funded by Regeneron/Sanofi),” Abstract of a presentation presented at the 81st European Atherosclerosis Society (EAS) Congress, Jun. 2-5, 2013, Lyon, France.Applicant
Hiriyama et al. (Jan. 1, 2014) “Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk—primary results from the phase 2 Yukawa study,” Circulation Journal. 78(5):1073-1082.Applicant
International Search Report with Written Opinion corresponding to International Patent Application No. PCT/EP2012/051321, dated Apr. 19, 2012, 10 pages.Applicant
International Search Report with Written Opinion corresponding to International Patent Application No. PCT/EP2012/057890, dated Aug. 28, 2012, 14 pages.Applicant
International Search Report with Written Opinion corresponding to International Patent Application No. PCT/US2015/040754, dated Oct. 14, 2015, 15 pages.Applicant
International Search Report with Written Opinion corresponding to International Patent Application No. PCT/US2015/040765, dated Nov. 26, 2015, 15 pages.Applicant
McKenney et al. (Jun. 2-5, 2013) “Dynamics between the monoclonal antibody SAR236553/REGN727, proprotein convertase subtilisin/kexin type 9 (PCSK9) and low-density lipoprotein cholesterol (LDL-C) levels (funding: Regeneron/Sanofi),” Presented as a poster presentation at the 81st European Atherosclerosis Society (EAS) Congress, Jun. 2-5, 2013, Lyon, France.Applicant
Schäfer et al. (Mar. 14-16, 2011) “Cholesterol lowering effect of SAR236553/REGN727, a fully human PCSK9 blocking monoclonal antibody in male Syrian hamster,” Presented as a poster at the Drugs Affecting Lipid Metabolism (DALM)—XVII International Symposium, Mar. 14-16, 2011, Doha, Qatar.Applicant
McPherson, 2013 Journal of the American College of Cardiology 61(4):437-439, “Remnant Cholesterol: Non-(HDL-C + LDL-C) as a Coronary Artery Disease Risk Factor”.Applicant
Varbo, et al., 2013 Journal of the American College of Cardiology 61(4):427-436, “Remnant Cholesterol as a Casual Risk Factor for Ischemic Heart Disease”.Applicant
Abifadel, et al., 2012 Atherosclerosis 223(2):394-400, “Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia”.Applicant
Abifadel, et al., 2009 Human Mutation 30(4):520-529, “Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease”.Applicant
Abifadel, et al. (2003) Nature Genetics 34(2):154-156, “Mutations in PCSK9 cause autosomal dominant hypercholesterolemia”.Applicant
Alborn, et al. (2007) Clinical Chemistry 53(10):1814-1819, “Serum proprotein convertase subtilisin Kexin type 9 is correlated directly with serum LDL cholesterol”.Applicant
Al-Mashhadi et al., 2013 Science Translation Medicine, American Association for the Advancement of Science 5(166):44-53, “Atherosclerosis: Familial hypercholesterolemia and atherosclerosis in clones minipigs created by DNA transposition of a human PCSK9 gain-of-function mutant”.Applicant
Attie and Seidah (2005) Cell Metabolism 5:290-292, “Dual regulation of the LDL receptor—Some clarity and new questions”.Applicant
Annex to Form PCT/ISA/206—Communication Relating to the Results of the Partial International Search for PCT/US2009/068013, dated Mar. 10, 2010.Applicant
Benjannet, et al. (2006) J. Biological Chemistry 281(41): 30561-30572, “The Proprotein Convertase (PC) PCSK9 Is Inactivated by Furin and/or PC5/6A”.Applicant
Chan, et al. (2009) PNAS 106(24):9820-9825, “A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates”.Applicant
Chaparro-Riggers, et al. (2012) J. Biological Chemistry 287(14):11090-11097, “Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9”.Applicant
Fallon, et al. (2000) J. Biological Chemistry 275(10):6790-6797, “Increased endosomal sorting of ligand to recycling enhances potency of an intereukin-2 analog”.Applicant
Fasano, et al., 2008 NMCD Nutrition Metabolism and Cardiovascular Diseases 18(1):S46, “45 Activity of Gain-of-Function PCSK9 Mutants on LDLR Correlates with Total-Cholesterol Values in ADH patients”.Applicant
Farnier, 2011 American Journal of Cardiovascular Drugs 11(3):145-152, “The role of proprotein convertase subtilisin/kexin type 9 in hyperlipidemia: Focus on therapeutic implications”.Applicant
Foote and Winter (1992) J. Mol. Biol. 224:487-499, “Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops”.Applicant
Grozdanov, et al. (2006) Biochem. Cell. Biol. 84:80-92, “Expression and localization of PCSK9 in rat hepatic cells”.Applicant
Hopkins, et al., 2011 Journal of Clinical Lipidology 5(3):S9-S17, “Familial Hypercholesterolemias: Prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia”.Applicant
Horton, et al. (2007) Trends Biochem Sci. 32(2): 71-77, “Molecular biology of PCSK9: its role in LDL metabolism”.Applicant
Igawa, et al. (2010) Nature Biotechnology 28(11):1203-1208, “Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization”.Applicant
Ito, et al. (1992) Federation of European Biochemical Societies 309(1):85-88, “The His-probe method: effects of histidine residues introduced into the complementarity-determining regions of antibodies on antigen-antibody interactions at different pH values”.Applicant
Lagace, et al. (2006) J Clin Invest Am Soc Clin Invest 116(11):2995-3005, “Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in liver of parabiotic mice”.Applicant
Lippi and Guidi (2000) QJ Med 93:75-84, “Lipoprotein(a): from ancestral benefit to modern pathogen?”.Applicant
Lose, et al., 2013 Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 33(4):447-460, “Evaluation of Proprotein Convertase Subtilisin/Kexin Type 9: Focus on Potential Clinical and Therapeutic Implications for Low-Density Lipoprotein Cholesterol Lowering”.Applicant
Lopez, Dayami (2008) Drug News & Perspectives Abstract 21(6): 323, “Inhibition of PCSK9 as a Novel Strategy for the Treatment of Hypercholesterolemia”.Applicant
Maeda, et a. (2002) J. Controlled Release 82:71-82, “pH-dependent receptor/ligand dissociation as a determining factor for intracellular sorting of ligands for epidermal growth factor receptors in rat hepatocytes”.Applicant
Marcovina and Koschinsky (1998) The American Journal of Cardiology 82(12A):57U-66U, “Lipoprotein(a) as a Risk Factor for Coronary Artery Disease”.Applicant
Maxwell and Breslow (2004) PNAS 101(18):7100-7105, “Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype”.Applicant
McKenney, et a. (2012) Journal of the American College of Cardiology 59(25):2335-2353, “Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy”.Applicant
Nakasako, et a. (1999) J. Mol. Biol. 291:117-134, “The pH-dependent structural variation of complementarity-determining region H3 in the crystal structures of the Fv fragment from an anti-dansyl monoclonal antibody”.Applicant
Naureckiene, et al. (2003) Archives of Biochemistry and Biophysics 420:55-67, “Functional characterization of Narc 1, a novel proteinase related to proteinase K”.Applicant
Noguchi, et al., 2010 Atherosclerosis 210(1):166-172, “The E32K variant of PCSK9 exacerbates the phenotype of familial hypercholesterolemia by increasing PCSK9 function and concentration in the circulation”.Applicant
Nordestgaard, et al. (2010) European Hear Journal 31:2844-2853, “Lipoprotein(s) as cardiovascular risk factor: current status”.Applicant
Parhofer (2011) Current Pharmaceutical Design 17:871-876, “Lipoprotein(a): Medical Treatment Options for an Elusive Molecule”.Applicant
Park, et al. (2004) J. Biol. Chem. 279: 50630-50638, “Lipids and Lipoproteins: Post-transcriptional Regulation of Low Density Lipoprotein Receptor Protein by Proprotein Convertase Subtilisin/Kexin Type 9a in Mouse Liver”.Applicant
Rashid, et al. (2005) PNAS 102(15):5374-5379, “Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9”.Applicant
Rhainds, et al., 2012 Clinical Lipidology 7(6):621-640, “PCSK9 inhibition and LDL cholesterol lowering: The biology of an attractive therapeutic target and critical review of the latest clinical trials”.Applicant
Sarkar, et al. (2002) Nature Biotechnology 20:908-913, “Rational cytokine design for increased lifetime and enhanced potency using pH-activated histidine switching”.Applicant
Seidah, et al. (2003) PNAS 100(3):928-933, “The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation”.Applicant
Stein, et al. (2012) New England Journal of Medicine 366:1108-1118, “Effect of a Monoclonal Antibody to PCSK9 on D Cholesterol”.Applicant
Stein and Swergold, 2013 Current Atherosclerosis Reports 15(310):1-14, “Potential of proprotein Convertase Subtilisin/Kexin Type 9 Based Therapeutics”.Applicant
Stein, et al., 2012 Obstetrical and Gynecological Survey 67(7):413-414, “Effect of a monoclonal antibody to PCSK9 on LDL cholesterol”.Applicant
Timms, et al. (2004) Human Genetics 114(4):349-353, “A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree”.Applicant
Watanabe, et al. (2009) J. Biological Chemistry 284(18):12373-12383, “Optimizing pH response of affinity between protein G and IgG Fc”.Applicant
Winter and Harris (1993) Immunology Today 14(6):243-246, “Humanized Antibodies”.Applicant
Bays H, Farnier M, Gaudet D, Weiss R, Lima Ruiz J, Watts GF, Gouni-Berthold I, Robinson J, Jones P, Severance R, Averna M, Steinhagen-Thiessen E, Colhoun HM, Zhao J, Du Y, Hanotin C, Donahue S. Efficacy and safety of combining alirocumab with atorvastatin or rosuvastatin versus statin intensification or adding ezetimibe in high cardiovascular risk patients: Odyssey Options I and II. Circulation. 2014;130:2105-2126.Applicant
Bays H; Gaudet D; Weiss R; Lima Ruiz J; Watts GF; Gouni-Berthold I; Robinson J; Zhao J; Hanotin C; Donahue S. PCSK9 Inhibitor Alirocumab as Add-on to Atorvastatin versus Other Lipid Treatment Strategies in Patients at High CVD Risk: Odyssey Options I. Circulation. 2014;130:A16194.Applicant
Cannon CP, Cariou B, Blom D, McKenney JM, Lorenzato C, Pordy R, Chaudhari U, Colhoun HM. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated daily statin: results from the Odyssey Combo II study; presented at ESC Congress Aug. 31, 2014, abstract not published.Applicant
Cannon CP, Cariou B, Blom D, McKenney JM, Lorenzato C, Pordy R, Chaudhari U, Colhoun HM; for the Odyssey Combo II Investigators. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the Odyssey Combo II randomized controlled trial Eur Heart J. 2015. doi:10.1093/eurheartj/ehv028 [epub ahead of print].Applicant
Catapano AL, Papadopoulos N. The safety of therapeutic monoclonal antibodies: implications for cardiovascular disease and targeting the PCSK9 pathway. Atherosclerosis 2013;228(1):18-28.Applicant
Duff et al. Biochem Journal, the Biochemical Society, vol. 419, No. 3, May 1, 2009 pp. 577-584.Applicant
Dufour R, Moriarty PM, Genestin E, Sasiela WJ, Du Y, Ferrand A-C; Ginsberg HN. Effect of REGN727/SAR236553 PCSK9 fully human monoclonal antibody in patients with elevated triglycerides/low high-density lipoprotein cholesterol: data from three phase 2 studies. Circulation 2012;126:Abstract A16127.Applicant
Farnier M, Kastelein JJP, Roth E, Taskinen MR, Ginsberg HN, Colhoun HM, Robinson JG, Merlet L, Brunet A, Pordy R, Baccara-Dinet MT. Relationship between alirocumab, PCSK9 and LDL-C levels: results from the Odyssey Mono Phase 3 trial of alirocumab 75 mg every 2 weeks. Atherosclerosis. 2014;235(2):e34-e35. [Abstract MP02E].Applicant
Foody J, Khan I, Lewis B. Attainment of low-density lipoprotein cholesterol goals in patients at high cardiovascular risk: results from a managed care population study. Circulation. 2013;128:A17254.Applicant
Gaudet D, Kereiakes D, McKenney J, Roth E, Hanotin C, Gipe D, Du Y, Ferrand A-C, Ginsberg H, Stein E. Alirocumab, a fully human monoclonal antibody to PCSK9, reduces high plasma Lp(a) concentration: pooled analysis of 352 patients from phase 2. J Clin Lipidol 2013:7(3):283-284.Applicant
Gaudet D, Kereiakes D, McKenney J, Roth E, Hanotin C, Gipe D, Du Y, Ferrand A-C, Ginsberg H, Stein E. Effect of Alirocumab, a Monoclonal Proprotein Convertase Subtilisin/Kexin 9 Antibody, on Lipoprotein(a) Concentrations (a Pooled Analysis of 150 mg Every 2 Weeks Dosing from Phase 2 Trials). Am J Cardiol. 2014;114(5):711-715.Applicant
Gaudet D, Kereiakes D, McKenney J, Roth E, Hanotin C, Gipe D, Du Y, Ferrand A-C, Ginsberg H, Stein E. Effect of SAR236553/REGN727 fully human monoclonal anti-proprotein convertase subtilisin/kexin type 9 antibody on plasma lipoprotein(a) concentrations: pooled analysis from three phase 2 studies (NCT:01266876; 01288469; 01288443). Circulation 2012;126:Abstract A14725.Applicant
Ginsberg HN, Rader DJ, Raal H, Guyton JR, Lorenzato C, Pordy R, Baccara-Dinet MT, Stroes E. Odyssey High FH: efficacy and safety of alirocumab in patients with severe heterozygous familial hypercholesterolemia. Circulation. 2014;130:2119.Applicant
Gusarova V, Howard VG, Okamoto H, Koehler-Stec EM , Papadopoulos N, Murphy AJ, Yancopoulos GD, Stahl N, Sleeman MW. Reduction of LDL cholesterol by a monoclonal antibody to PCSK9 in rodents and nonhuman primates. Clin Lipidol 2012;7(6):737-743.Applicant
Hochleitner et al., Characterization of a discontinuous epitope of the human immunodeficiency virus ˜HIV! core protein p24 by epitope excision and differential chemical modification followed by mass spectrometric peptide mapping analysis; Protein Science 2000, 9:487-496. Cambridge University Press.Applicant
Hopkins PN, Swergold GD, Mellis S, Bruckert E, Luc G, Mendoza J, Du Y, Krempf M. A randomized placebo-phase clinical trial with the monoclonal antibody alirocumab demonstrates reductions in low-density lipoprotein cholesterol in patients with proprotein convertase subtilisin/kexin type 9 gain-of-function mutations. Circulation. 2013;128:A17156.Applicant
Hovingh GK, Davidson MH, Kastelein JJ, O'Connor AM. Diagnosis and treatment of familial hypercholesterolaemia. Eur Heart J 2013;34(13):962-971.Applicant
International Preliminary Report on Patentability dated Jul. 30, 2013 for International application No. PCT/EP12/051321, 7 pages.Applicant
International Search Report and Written Opinion dated Aug. 19, 2015 for International application No. PCT/US2015/015633, 23 pages.Applicant
International Search Report and Written Opinion dated Apr. 16, 2015 for International Application No. PCT/US2014/060109 (19 pages).Applicant
International Search Report and Written Opinion dated Feb. 3, 2015 for International Application No. PCT/US2014/065149 (17 pages).Applicant
International Search Report and Written Opinion dated Jun. 12, 2015 for International Application No. PCT/US2015/020564 (20 pages).Applicant
International Search Report dated Aug. 2, 2012 for International application No. PCT/EP12/051321, (4 pages).Applicant
Jones P, Bays H, Chaudhari U, Pordy R, Lorenzato C, Miller K, Robinson J. Pooled safety and adverse events in nine randomized, placebo-controlled, phase 2 and 3 clinical trials of alirocumab. J Am Coll Cardiol 2015;65(10_S):A1363.Applicant
Junghans et al.: Anti-Tac-H, a Humanized Antibody to the Interleukin 2 Receptor with New Features for Immunotherapy in Malignant and Immune Disorders; Cancer Research, 50. 1495-1502; Mar. 1, 1990.Applicant
Kastelein JJP, Ginsberg HN, Langslet G, Kees Hovingh G, Ceska R, Dufour R, Blom D, Civeira F, Krempf M, Farnier M. Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolaemia not adequately controlled with current lipid-lowering therapy: results of Odyssey FH I and FH II studies; presented at ESC Congress Aug. 31, 2014, abstract not published.Applicant
Kereiakes DJ, Robinson JG, Cannon CP, Lorenzato C, Pordy R, Chaudhari U, Colhoun HM. Efficacy and safety of alirocumab in high cardiovascular risk patients with suboptimally controlled hypercholesterolemia on maximally tolerated doses of statins: The Odyssey Combo I study. Circulation. 2014;130:2119.Applicant
Kereiakes DJ, Robinson JG, Cannon CP, Lorenzato C, Pordy R, Chaudhari U, Colhoun HM. Efficacy and safety of the PCSK9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the Odyssey Combo I study. Am Heart J. 2015. In press. DOI: http://dx.doi.org/10.1016/j.ahj.2015.03.004.Applicant
Koren M, Stein E, McKenney JM, Gipe D, Hanotin C, Ferrand A-C, Wu R, Dufour R. Efficacy, safety and tolerability of 150 mg Q2W dose of the anti-PCSK9 mAb, REGN727/SAR236553: data from 3 phase 2 studies. Eur Heart J 2012;33(Abstract Supplement);37. Abstract 429.Applicant
Koren MJ, Kereiakes D, Pourfarzib R, Winegar D, Banerjee P, Hamon S, Hanotin C, McKenney JM. Effects of alirocumab, a fully human monoclonal antibody to proprotein convertase subtilisin/kexin type 9, on lipoprotein particle concentrations determined by nuclear magnetic resonance: substudy of a randomized double-blind phase II clinical trial. J Am Coll Cardiol 2014;63(12 Suppl 1): A1373.Applicant
Koren MJ, Roth EM, McKenney JM, Gipe D, Hanotin C, Ferrand AC, Wu R, Dufour R. Safety and efficacy of alirocumab 150 mg every 2 weeks, a fully human proprotein convertase subtilisin/kexin type 9 monoclonal antibody: a Phase II pooled analysis. Postgrad Med 2015;22:1-8.Applicant
Koren MJ, Stein E, Roth E, McKenney JM, Gipe D, Hanotin C, Ferrand A-C, Wu R, Dufour R. Efficacy, safety and tolerability of alirocumab 150 mg Q2W, a fully human PCSK9 monoclonal antibody: a pooled analysis of 352 patients from phase 2. J Clin Lipidol 2013:7(3)279-280.Applicant
Krauss RM, Banerjee P, Hamon S, Hanotin C, Sasiela B, Koren MJ, McKenney JM. Alirocumab, a fully human monoclonal antibody to proprotein convertase subtilisin/kexin type 9, and its effects on lipoprotein subtractions determined by ion mobility. Circulation. 2014;130:A15525.Applicant
Kühnast S, van der Hoorn JW, Pieterman E, Sasiela WJ, Gusarova V, Peyman A, Schafer H-L, Schwahn U, Jukema JW, Princen HM. PCSK-9 monoclonal antibody alirocumab dose-dependently decreases atherosclerosis development and enhances the effects of atorvastatin in APOE*3Leiden.CETP mice. Circulation. 2013;128:A15823.Applicant
Kühnast S, van der Hoorn JWA, Pieterman EJ, van den Hoek AM, Sasiela WJ, Gusarova V, Peyman A, Schäfer H-L, Schwahn U, Jukema JW, Princen HMG. Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin. J Lipid Res. 2014;55(10):2103-2112.Applicant
Lambert G, Chatelais M, Petrides F, Passard M, Thedrez A, Rye KA, Schwahn U, Gusarova V, Blom DJ, Sasiela W, Marais AD. Normalization of Low-Density Lipoprotein Receptor Expression in Receptor Defective Homozygous Familial Hypercholesterolemia by Inhibition of PCSK9 With Alirocumab. J Am Coll Cardiol. 2014;64(21):2299-2300.Applicant
Lambert G, Sjouke B, Choque B, Kastelein JJ, Hovingh GK. The PCSK9 decade. J Lipid Res 2012;53(12):2515-2524.Applicant
Lunven C, Paehler T, Lewanczyk P, Poitiers F, Brunet A, Rey J, Hanotin C, Sasiela WJ. A randomized study of the relative bioavailability, pharmacodynamics, and safety of alirocumab, a fully human monoclonal antibody to proprotein convertase subtilisin/ kexin type 9, after single subcutaneous administration at three different injection sites in healthy subjects. J Am Coll Cardiol 2014;63(12 Suppl 1): A1377.Applicant
Lunven C, Paehler T, Poitiers F, Brunet A, Rey J, Hanotin C, Sasiela WJ. A randomized study of the relative pharmacokinetics, pharmacodynamics and safety of alirocumab, a fully human monoclonal antibody to PCSK9, after single subcutaneous administration at three different injection sites in healthy subjects. Cardiovasc Ther. Dec. 2014;32(6):297-301.Applicant
McKenney J, Koren M, Kereiakes D, Hanotin C, Ferrand A-C. A randomized, double-blind, placebo-controlled trial of the safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, REGN727/SAR236553, in patients with primary hypercholesterolemia (NCT: 01288443). Presented as a late-breaking oral presentation at the American College of Cardiology (ACC) Annual Scientific Session, Mar. 24-27, 2012, Chicago, Illinois, USA.Applicant
Missouri DU Report, Drug Use Review Newsletter, vol. 8, No. 6, Oct./Nov. 2003 “Statin Therapy” pp. 1-9.Applicant
Moriarty PM, Jacobson TA, Bruckert E, Thompson PD, Guyton JR, Baccara-Dinet MT, Gipe D. Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: Design and rationale of Odyssey Alternative, a randomized Phase 3 trial. J Clin Lipidol. 2014;8(6):554-561.Applicant
Moriarty PM, Lecorps G, Hanotin C, Pordy R, Roth EM. Homogeneity of treatment effect of REGN727/SAR236553, a fully human monoclonal antibody against PCSK9, in lowering LDL-C: data from three phase 2 studies. Eur Heart J. 2013;34(Suppl 1):doi:10.1093/eurheartj/eht307.142.Applicant
Moriarty PM, Thompson PD, Cannon CP, Guyton JR, Bergeron J, Zieve H, Bruckert E, Jacobson TA, BaccaraDinet MT, Zhao J, Pordy R, Gipe R. Odyssey Alternative: Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody, alirocumab, versus ezetimibe, in patients with statin intolerance as defined by a placebo run-in and statin rechallenge arm. Circulation. 2014;130:2108.Applicant
Pordy R, Lecorps G, Bessac L, Sasiela WJ, Ginsberg H. Alirocumab, a fully human monoclonal antibody to proprotein convertase subtilisin/kexin type 9: therapeutic dosing in phase 3 studies. J Clin Lipidol 2013:7(3):279.Applicant
Ramanathan A, Gusarova V, Kyratsous C. Role of alirocumab (proprotein convertase subtilisin/kexin type 9 antibody) on CD81 levels and hepatitis C virus entry into hepatocytes. Circulation. 2013;128:A12052.Applicant
Ray KK, Foody J, Khan I, Lewis BE. Attainment of low-density lipoprotein cholesterol goals in patients at very high cardiovascular risk in the United Kingdom: results from a general practice population study. Value Health 2013;16(7):A513.Applicant
Rey J, Poitiers F, Paehler T, Brunet A, Pinquier JL, Hanotin C, Sasiela B. Randomized, partial blind study of the pharmacodynamics, pharmacokinetics and safety of multiple subcutaneous doses of alirocumab, a fully human monoclonal antibody to proprotein convertase subtilisin/kexin type 9, administered every 4 weeks alone or in combination with ezetimibe or fenofibrate in healthy subjects. J Am Coll Cardiol 2014;63(12 Suppl 1):A1375.Applicant
Robinson J, Farnier M, Chaudhari U, Sasiela B, Lorenzato C, Miller K, Kastelein JJP. Adverse events in patients with low-density lipoprotein cholesterol levels <25 or <15 mg/dL on at least two consecutive visits in fourteen randomized, controlled, clinical trials of alirocumab. J Am Coll Cardiol 2015;65(10_S):A1350.Applicant
Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes E, Langslet G, Raal FJ, El Shahawy M, Koren MJ, Lepor N, Lorenzato C, Pordy R, Chaudhari U, Kastelein JJP. Long-term safety, tolerability and efficacy of alirocumab versus placebo in high cardiovascular risk patients: first results from the Odyssey Long Term study in 2,341 patients. Circulation. 2014;130:2120.Applicant
Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, Shahawy ME, Koren MJ, Lepor NE, Lorenzato C, Pordy R, Chaudhari U, Kastelein JJ; Odyssey Long Term Investigators. Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events. N Eng J Med. 2015.Applicant
Roth E, Taskinen M-R, Ginsberg HN, Kastelein JJP, Colhoun HM, Robinson JG, Merlet L, Pordy R, Baccara-Dinet MT. A 24-week study of alirocumab monotherapy versus ezetimibe: The first phase 3 data of a proprotein convertase subtilisin/kexin type 9 inhibitor. J Am Coll Cardiol 2014;63(12 Suppl 1): A.Applicant
Roth EM, McKenney J, Hanotin C, Asset G, Stein E. The effects of co-administering a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, REGN727/SAR236553, with 10 and 80 mg atorvastatin compared to 80 mg atorvastatin alone in patients with primary hypercholesterolemia (NCT: 01288469). J Am Coll Cardiol 2012;59:E1620.Applicant
Roth EM, McKenney JM, Hanotin C, Asset G, Stein EA. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med. 2012;367(20):1891-1900.Applicant
Roth EM, McKenney JM. Odyssey Mono: effect of alirocumab 75 mg subcutaneously every 2 weeks as monotherapy versus ezetimibe over 24 weeks. Future Cardiol 2015;11(1):27-37.Applicant
Roth EM, Taskinen M-R, Ginsberg H, Kastelein JJP, Colhoun HM, Robinson JG, Merlet L, Pordy R, Baccara-Dinet MT. Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24 week, double-blind, randomized Phase 3 trial. Int J Cardiol. 2014;176(1):55-61.Applicant
Schwartz GG, Bessac L, Berdan LG, Bhatt DL, Bittner V, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Mahaffey KW, Moryusef A, Pordy R, Roe MT, Rorick T, Sasiela WJ, Shirodaria C, Szarek M, Tamby J-F, Tricoci P, White H, Zeiher A, Steg PG. Effect of alirocumab, a monoclonal antibody to pcsk9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the odyssey outcomes trial. Am Heart J. 2014;168(5):682-689.e1.Applicant
Steen D, Khan I, Becker L, Gorcyca K, Foody J. Attainment of Lipid Levels in Patients at High Cardiovascular Risk: Results from a U.S. Managed Care Population Study. Circulation. 2014;130:A19949.Applicant
Steen D, Khan I, Song X, Sanchez R, Gorcyca K, Hollenbeak CS, Foody J. Cardiovascular Event Rates in a High-Risk Managed Care Population in the United States. J Am Coll Cardiol 2015;65(10_S):A1647.Applicant
Stein E, Bergeron J, Gaudet D, Weiss R, Gipe D, Wu R, Dufour R, Pordy R. Safety and efficacy of a monoclonal antibody to PCSK9, REGN727/SAR236553, in statin-treated heterozygous familial hypercholesterolemia patients. Presented as an oral presentation at the 80th European Atherosclerosis Society (EAS) Congress, May 25-28, 2012, Milan, Italy. Abstract 1398.Applicant
Stein EA, Bergeron J, Gaudet D, Weiss R, Dufour R, Du Y, Yang F, Andisik M, Toni A, Pordy R, Gipe D. One year open-label treatment with alirocumab 150 mg every two weeks in heterozygous familial hypercholesterolemic patients. Lancet 2012 380:29-36.Applicant
Stroes E, Guyton JR, Farnier M, Rader D, Moriarty PM, Bergeron J, Langslet G, Lepor N, Civeira F, Gaudet D, Watts GF, Manvelian G, Lecorps G, Zhao J, Baccara-Dinet M, Roth EM. Efficacy and safety of different dosing regimens of alirocumab (starting doses of 75 mg every two weeks and 150 mg every four weeks) versus placebo in patients with hypercholesterolemia not treated using statins: the Odyssey Choice II study. J Am Coll Cardiol 2015;65(10_S):A1370.Applicant
Sullivan, et al. Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant Patients. JAMA. Dec. 19, 2012. vol. 308, No. 23. pp. 2497-2506.Applicant
Swergold G, Biedermann S, Renard R, Du Y, Nadler D, Wu R, Mellis S, Lisbon E. REGN727/SAR236553, a fully-human monoclonal antibody to proprotein convertase subtilisin kexin 9 (PCSK9), decreases ApoB and non-HDL-C when administered intravenously to healthy volunteers. J Clin Lipidol 2011;5(3):219.Applicant
Swergold G, Biedermann S, Renard R, Nadler D, Wu R, Lisbon EA, Gutierrez MJ, Mellis S. REGN727/SAR236553, a fully human proprotein convertase subtilisin kexin 9 (PCSK9) monoclonal antibody: effects on safety and lipid and lipoprotein profiles when administered subcutaneously. J Am Coll Cardiol 2011;57(14s1):E2023.Applicant
Swergold G, Biedermann S, Renard R, Nadler D, Wu R, Mellis S. Safety, lipid, and lipoprotein effects of REGN727/SAR236553, a fully human proprotein convertase subtilisin kexin 9 (PCSK9) neutralizing monoclonal antibody administered intravenously to healthy volunteers. Circulation 2010;122:Abstract A23251.Applicant
Swergold G, Smith W, Mellis S, Logan D, Webb C, Wu R, Du Y, Krans T, Gasparino E, Stein EA. Inhibition of proprotein convertase subtilisin/kexin type 9 with a monoclonal antibody REGN727/SAR236553, effectively reduces low-density-lipoprotein cholesterol, as mono or add-on therapy in heterozygous familial and non-familial hypercholesterolemia. Circulation 2011;124:Abstract A16265.Applicant
Teramoto T, Kobayashi M, Uno K, Takagi Y, Matsuoka O, Sugimoto M, Inoue S, Minami F, Baccara-Dinet MT. Efficacy and safety of alirocumab in Japanese patients with hypercholesterolemia on stable statin therapy: first data with the 75 mg every two weeks dose. Circulation. 2014;130:A13651.Applicant
Toth PP, Hamon S, Jones SR, Joshi PH, Martin SS, Pordy R, Hanotin C. Alirocumab, a proprotein convertase subtilisin/kexin type 9 monoclonal antibody, reduces cholesterol concentrations of all serum low-density lipoprotein cholesterol fractions. Circulation. 2013;128:A17313.Applicant
Toth PP, Hamon S, Jones SR, Martin SS, Joshi PH, Kulkarni K, Banerjee P, Hanotin C. Proprotein convertase subtilisin/kexin 9 monoclonal antibody therapy significantly reduces apoprotein CII and CIII levels in serum. Atherosclerosis. 2014;235(2):e107-e108. [Abstract 593].Applicant
Van der Hoorn JWA, Kuhnast S, Pieterman E, van der Hoek AM, Sasiela WJ, Gusarova V, Peyman A, Schafer H-L, Schwahn U, Jukema JW, Princen HMG. Alirocumab, a monoclonal antibody to PCSK-9, dose-dependently decreases atherosclerosis, improves plaque stability and shows additive effects with atorvastatin in APOE*3Leiden.CETP mice. Atherosclerosis. 2014;235(2):e19. [Abstract WS16].Applicant
Wong ND, Chuang J. Residual Dyslipidemia According to LDL-C, non-HDL-C and Apolipoprotein B by Cardiovascular Risk Category in Statin Treated US Adults. J Clin Lipidol. 2014;8:323-324. Presented as a poster presentation at the National Lipid Association Scientific Sessions, May 1-4, 2014, Orlando, Florida, USA.Applicant
Anonymous: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome. Archive from ClinicalTrials.gov for NCT01663402 on Mar. 11, 2014 (3 pages).Applicant
Anonymous: Long-term Safety and Tolerability of Alirocumab SAR236553 (REGN727) in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid Modifying Therapy: A Randomized, Double-Blind, Placebo-Controlled Study. Archive from ClinicalTrials.gov for NCT01507831 on Jun. 27, 2013 (3 pages).Applicant
Blom, Dirk J. et al.: “A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia” vol. 370, No. 19, May 8, 2014 pp. 1809-1819.Applicant
Costet. PCSK9 inhibitors as LDL cholesterol-lowering agents: Rationale, concerns and preliminary outcomes. Drugs of the Future. May 1, 2012. vol. 37, No. 5, pp. 331-341.Applicant
Gonnet et al.: Exhaustive Matching of the Entire Protein Sequence Database; Science; 1992, vol. 256, pp. 1443-1445.Applicant
Gusarova V, Sleeman M, Swergold G, Sasiela B, Stahl N, Yancopoulos G, Murphy A. Fully human antibody that blocks PCSK9 demonstrates reduction in LDL-C preclinically and in early clinical trials. Abstract of oral presentation at the Keystone Symposia on Molecular and Cellular Biology, Mar. 25-30, 2012, Montana, USA.Applicant
Haddley et al. Alirocumab Anti-Proprotein Convertase 9 (PCSK9) Mab Treatment of Hypercholesterolemia. Drugs of the Future; Apr. 1, 2013. vol. 38, No. 4. pp. 215-216.Applicant
Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes E, Langslet G, Raal FJ, El Shahawy M, Koren MJ, Lepor N, Lorenzato C, Pordy R, Chaudhari U, Kastelein JJP. Long-term safety, tolerability and efficacy of alirocumab versus placebo in high cardiovascular risk patients: first results from the Odyssey Long Term study in 2,341 patients; presented at ESC Congress Aug. 31, 2014, abstract not published.Applicant
Roth et al. Alirocumab for hyperlipidemia: physiology of PCSK9 inhibition, pharmacodynamics and Phase I and II clinical trial results of a PCSK9 monoclonal antibody. Future Cardiology. Mar. 2014; vol. 10, No. 2. pp. 187-197. 183-199.Applicant
Shao W. New Therapies for Lowering LDL-C: Targeting PCSK9. Abstract of oral presentation at the Sino-American Pharmaceutical Professionals Association—2014 Scientific Symposium, Apr. 26, 2014, New Jersey, USA.Applicant
Swergold GD, et al. Identification and characterization of patients with autosomal dominant hypercholesterolemia caused by gain-of-function mutations in proprotein convertase subtilisin/kexin type 9 and comparison with patients with Familial Hypercholesterolemia (FH) and Familial Defective apolipoprotein B (FDB). Abstract of a poster presentation at the American Society of Human Genetics (ASHG), Oct. 22-26, 2013, Boston, USA.Applicant
Chinese Patent Application No. 201280015477.6, Office Action dated Dec. 2, 2014 with English summary, 12 pages.Applicant
Chinese Patent Application No. 201280015571.1, Office Action dated Sep. 3, 2014 with English summary, 12 pages.Applicant
European Patent Application No. 12701015.5, Communication pursuant to Article 94(3) EPC dated Apr. 24, 2015, 9 pages.Applicant
European Patent Application No. 12701015.5, Communication pursuant to Article 94(3) EPC dated May 30, 2014, 8 pages.Applicant
European Patent Application No. 12701742.4, Communication pursuant to Article 94(3) EPC dated May 28, 2014, 8 pages.Applicant
Dube, et al. (2012) Curr Opin Lipidol 23(2):133-140, “Lipoprotein(a): more interesting than ever after 50 years”.Applicant
Koschinsky and Boffa (2014) Endocrinology and Metabolism Clinics of North America 43(4): 949-962, “Lipoprotein(a): An Important Cardiovascular Risk Factor and a Clinical Conundrum”.Applicant
Lamon-Fava, et al. (2011) Journal of Lipid Research 52:1181-1187 “Lipoprotein(a) levels, apo(a) isoform size, and coronary heart disease risk in the Framingham Offspring Study”.Applicant
Third Party Observation for European Patent Application No. 12761864.3 dated Feb. 24, 2016.Applicant
Tsimikas, et al. (2015) The Lancet 386(10002):1472-1483, “Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study”.Applicant
Romagnuolo, et al. (2015) The Journal of Biological Chemistry 290(18):11649-11662, “Lipoprotein(a) Catabolism is Regulated by Proprotein Convertase Subtilisin/Kexin Type 9 through the Low Density Lipoprotein Receptor”.Applicant
Barbie and Lefranc, 1998 Exp. Clin. Immunogenet. 15:171-183, “The Human Immunoglobulin Kappa Variable (IGKV) Genes and Joining (IGKJ) Segments”.Applicant
Breen, et al. (2001) Pharmaceutical Research 18(9): 1345-1353, “Effect of moisture on the stability of a lyophilized humanized monoclonal antibody formulation”.Applicant
Carpenter, 1997 Pharm. Res. 14(8): 969-975, Rational Design of Stable Lyophilized Protein Formulations: Some Practical Advice.Applicant
Daugherty, et al., 2006 Advanced Drug Delivery Reviews 58: 686-706, “Formulation and delivery issues for monoclonal antibody therapeutics”.Applicant
Katayama, et al. 2004 J. Pharm. Sci. 93(10): 2609-2623, “Retrospective statistical analysis of lyophilized Protein Formulations of Progenipoietin Using PLS: Determination of the Critical Parameters for Long-Term Storage Stability”.Applicant
Lefranc, M.-P., et al., IMGT®, the international ImMunoGeneTics information system®, Nucl. Acids Res, 37, D1006-D1012 (2009).Applicant
Majumdar, et al. (2011) Journal of Pharmaceutical Sciences 100(7):2563-2573, “Evaluation of the effect of syringe surfaces on protein formulations”.Applicant
Meehan et al.,1996, J. Controlled Release 46:107-116, “A microinfusor device for the delivery of therapeutic levels of peptides and macromolecules”.Applicant
Robinson, N., 2002, PNAS, 99(8):5283-5288 “Protein Deamidation”.Applicant
Scaviner, D. et al., 1999 Exp. Clin. Immunogenet. 16:234-240 “Protein Displays of the Human Immunoglobulin Heavy, Kappa and Lambda Variable and Joining Regions”.Applicant
Varret, et al., 1999 Am. J. Hum. Genet. 64: 1378-1387, “A third major locus for autosomal dominant hypercholesterolemia Maps to 1p. 34.1-p. 32”.Applicant
Wang, 1999 International J. Pharmaceutics 185(2): 129-188, “Instability, stabilization, and formulation of liquid protein pharmaceuticals”.Applicant
Webb, et al. 2002 J. Pharm. Sci. 91(2): 543-558, “A new mechanism for decreasing aggregation of Recombinant Human Interferon-γ by a Surfactant: Slowed Dissolution of Lyophilized Formulations in a Solution Containing 0.03% Polysorbate 20”.Applicant
Davidson, et al. (2011) Journal of Clinical Lipidology 5:338-367, “Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists”.Applicant
Rader, et al. (1995) The Journal of Clinical Investigation, Inc. 95:1403-1408, “The Low Density Lipoprotein Receptor Is Not Required for Normal Catabolism of Lp(a) in Humans”.Applicant
Kostner, et al. (2013) European Heart Journal 34:3268-3276, “When should we measure lipoprotein (a)?”.Applicant
Jorgensen et al. (2013) European Heart Journal 34:1826-1833, “Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as casual risk factors for myocardial infarction”.Applicant
Kawashiri, et al. (2012) Circulation 126(21):13869, “Statin Therapy Improves Fractional Catabolic Rate of LDL without Affecting Impaired VLDL and VLDL Remnant Catabolism in Homozygous FH Patient Due to PCSK9 Gene Mutation: Evidence from Kinetic Study with Stable Isotope”.Applicant
Toth, et al., (2013) Circulation 128(22):17492, “Alirocumab, a Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibody, Reduces Cholesterol Concentrations of Serum Remnant Lipoprotein Fractions, Very Low-Density Lipoproteins and Triglycerides”.Applicant
Varbo, et al., (2013) Journal of the American College of Cardiology 61(4):427-436, “Remnant Cholesterol as a Casual Risk Factor for Ischemic Heart Disease”.Applicant
Partial International Search Report dated Nov. 6, 2014 for International Application No. PCT/US2014/040163.Applicant
Bays et al. (2015) J Clin Lipidol. 9(3):471-472 Abstract 183 “Alirocumab treatment effect on non-HDL-C: pooled analyses of ten Phase 3 trials in the Odyssey program”.Applicant
Bee et al. (2009) Journal of Pharmaceutical Sciences 98(9): 3290-3301 “Precipitation of a monoclonal antibody by soluble tungsten”.Applicant
Berthold and Berthold (2013) Atherosclerosis Supplements 14:10-5 “Hyperlipoproteinemia(a): Clinical significance and treatment options”.Applicant
Cariou et al. (May 23-26, 2015) International Symposium on Atherosclerosis. Abstract No. 1039 “Patient and physician perspectives on administration of the PCSK9 monoclonal antibody alirocumab, an injectable medication to lower LDL-C levels”.Applicant
clinicaltrials.gov (Dec. 23, 2010) “View of NCT01266876,” US National Institutes of Health. [accessible on the internet at: https://clinicaltrials.gov/archive/NCT01266876/2010_12_23].Applicant
clinicaltrials.gov (Feb. 1, 2011) “View of NCT01288443,” US National Institutes of Health. [accessible on the internet at: https://clinicaltrials.gov/archive/NCT01288443/2011_02_01).Applicant
clinicaltrials.gov (First Received: Aug. 8, 2012) “View of NCT01663402,” US National Institutes of Health. [accessible on the internet at: https://clinicaltrials.gov/ct2/show/NCT01663402].Applicant
clinicaltrials.gov (First Received: Jun. 8, 2012) “View of NCT01617655,” US National Institutes of Health. [accessible on the internet at: https://clinicaltrials.gov/ct2/show/NCT01617655?term=NCT01617655&rank=1].Applicant
clinicaltrials.gov (First Received: Jan. 6, 2012) “View of NCT01507831,” US National Institutes of Health. [accessible on the internet at: https://clinicaltrials.gov/ct2/show/NCT01507831?term=NCT01507831&rank=1].Applicant
clinicaltrials.gov (First Received: Feb. 1, 2011) “View of NCT01288469,” US National Institutes of Health. [accessible on the internet at: https://clinicaltrials.gov/ct2/show/NCT01288469?term=NCT01288469&rank=1].Applicant
clinicaltrials.gov (First Received: Oct. 8, 2012) “View of NCT01709500,” US National Institutes of Health. [accessible on the internet at: https://clinicaltrials.gov/ct2/show/NCT01709500?term=NCT01709500&rank=1].Applicant
clinicaltrials.gov (First Received: Jul. 16, 2012) “View of NCT01644175,” US National Institutes of Health. [accessible on the internet at: https://clinicaltrials.gov/ct2/show/NCT01644175?term=NCT01644175&rank=1].Applicant
clinicaltrials.gov (First Received: Jul. 16, 2012) “View of NCT01644188,” US National Institutes of Health. [accessible on the internet at: https://clinicaltrials.gov/ct2/show/NCT01644188?term=NCT01644188&rank=1].Applicant
clinicaltrials.gov (First Received: Jul. 9, 2010) “View of NCT01161082,” US National Institutes of Health. [accessible on the internet at: https://clinicaltrials.gov/ct2/show/NCT01161082?term=NCT01161082&rank=1].Applicant
clinicaltrials.gov (First Received: Jul. 17, 2012) “View of NCT01644474,” US National Institutes of Health. [accessible on the internet at: https://clinicaltrials.gov/ct2/show/NCT01644474?term=NCT01644474&rank=1].Applicant
Dufour et al. (2014) Can J Cardiol 30(10 suppl):S338 Abstract 546 “One year open-label treatment with alirocumab 150 mg every two weeks in heterozygous familial hypercholesterolemic patients”.Applicant
Gaudet et al. (2017) Am Journal Cardiology 119:40-46 “Effect of Alirocumab on Lipoprotein(a) Over ‡1.5 Years (from the Phase 3 Odyssey Program)”.Applicant
Gorcyca et al. (2015) J Clin Lipidol. 9(3):424 Abstract 118 “Prevalence of atherosclerotic cardiovascular disease and diabetes in the United States”.Applicant
Hopkins et al. (Dec. 2015) Circ Cardiovasc Genet. 8(6):823-831 “Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and its Specific Treatment with Alirocumab, a PCSK9 Monoclonal Antibody”.Applicant
Huang et al. (May 2015) J Clin Lipidol. 9(3):437-438 Abstract 134 “Clinical characteristics and unmet need among real-world atherosclerotic cardiovascular disease (ASCVD) patients stratified by statin use”.Applicant
ISR with WO for International Patent Application No. PCT/EP2012/051321 dated Apr. 19, 2012.Applicant
ISR and WO for International Application No. PCT/US2014/046170 dated Oct. 2, 2014.Applicant
ISR and WO from PCT/US2014/040050 dated Oct. 6, 2014.Applicant
ISR with WO for International Patent Application No. PCT/EP2015/055369 dated May 21, 2015.Applicant
ISR with WO for International Patent Application No. PCT/US2014/041204 dated Oct. 17, 2014.Applicant
ISR for International Application No. PCT/US2013/057898 dated Feb. 13, 2014.Applicant
Kolata (2015) The New York Times “Praluent Looks Cheap to Those with Extreme Cholesterol” Website [Online] Available Website: www.nytimes.com/2015/07/28/health/praluent-looks-cheap-to-those-with-extreme-cholesterol.html; Last Update: unknown; Accessed on: Nov. 8, 2016.Applicant
Konrad et al. (2011) Lipids in Health and Disease 10(1):38 “Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents”.Applicant
Kuiper (2015) Pharma ISA Poster “Statin use and low density lipoprotein cholesterol goal attainment among a high cardiovascular risk population in the Netherlands”.Applicant
Li et al. (2009) Recent Patents on DNA and Gene Sequences 3(3):201-212 “Recent Patents on PCSK9: A New Target for Treating Hypercholesterolemia”.Applicant
Miettinen et al. (1971) Circulation 44(5):842-850 “Cholesterol production in obesity”.Applicant
Moon (2007) Cardiology 108:282-289 “Lipoprotein(a) and LDL Particle Size are Related to the Severity of Coronary Artery Disease”.Applicant
Moriarty et al. (2015) J Clin Lipidol. 9(6):758-769 “Efficacy and safety of alirocumab versus ezetimibe in statin-intolerant patients, with a statin-re-challenge arm: The Odyssey Alternative randomized trial”.Applicant
Moriarty (2015) 10th International Society for Apheresis Congress XP55317363, Cancun Mexico “PCSK9 Inhibitors and their Effect on Patients who are Statin Intolerant or Receiving Lipoprotein-apheresis”.Applicant
Office Action from CN2012-80015477.6 dated Dec. 2, 2014 with English summary.Applicant
Office Action from CN2012-80015571.1 dated Sep. 3, 2014 with English summary.Applicant
Office Action Article 94(3) EP App No. 12701742.4 dated Jun. 1, 2015.Applicant
Ray (2015) Clin Lipidol. 10(1):9-12 “Alirocumab: an investigational treatment for hypercholesterolemia”.Applicant
Reyes-Soffer et al. (2015) Arterioscler Thromb Vasc Biol 35:A129 “Effects of a proprotein convertase subtilisin/kexin type 9 inhibitor, alirocumab, on lipid and lipoprotein metabolism in normal subjects”.Applicant
Roth et al. (2015) J. Clin. Lipidol. 37(9):1945-1954 “Patient and physician perspectives on administration of the PCSK9 monoclonal antibody alirocumab, an injectable medication to lower LDL-C levels”.Applicant
Roth et al. (2015) International Symposium on Atherosclerosis, Abstract No. 254 “Phase 3 Randomized Trial Evaluating Alirocumab Every Four Weeks Dosing as Add-on to Statin or as Monotherapy: Odyssey Choice I”.Applicant
Saeedi and Frohlich (2016) Clinical Diabetes and Endocrinology 2:7 “Lipoprotein (a), an independent cardiovascular risk marker”.Applicant
Sahebkar et al. (2013) Clinical Therapeutics 35(8):1082-1098 “New LDL-Cholesterol Lowering Therapies: Pharmacology, Clinical Trials, and Relevance to Acute Coronary Syndromes”.Applicant
Shields et al. (2002) Journal of Biological Chemistry 277(30):26733-26740 “Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcγRIII and antibody-dependent cellular toxicity”.Applicant
Stahl (2010) “Early Clinical Development #1 REGN727: anti-PCSK9,” Regeneron Pharmaceuticals. Accessible on the Internet at URL: http://files.shareholder.com/downloads/REGN/0x0x387214/534aaeb6-5e66-4e8f-86a9-0f9cac20d72f/REGN%20Investor%20Day%20Early%20Clinical%20Development1.pdf.Applicant
Stein et al. (2012) The Lancet 380:29-36 “Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygofamilial hypercholesterolemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomized controlled trial”.Applicant
Steinberg et al. (2009) Proceedings of the National Academy of Sciences USA 106(24):9546-9547 “Inhibition of PCSK9: a powerful weapon for achieving ideal LDL cholesterol levels”.Applicant
Stroes et al. (2014) J. Am. Coll. Cardiol. 63(23):2541-2548 “Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance”.Applicant
Wang et al. (2007) Journal of Pharmaceutical Sciences 96(1):1-26 “Antibody Structure, Instability, and Formulation”.Applicant
Wang et al. (2009) Clin. Pharmacology 49(9):1012-1024.Applicant
Westerterp et al. (2006) Vasc Biol 26(11):2552-2559 “Cholesteryl Ester Transfer Protein Decreases High-Density Lipoprotein and Severely Aggravates Atherosclerosis in APOE*3-Leiden Mice, Arterioscler Thromb”.Applicant
Defesche et al. (Jun. 2-5, 2013) Presentation presented at the 81st European Atherosclerosis Society (EAS) Congress, Lyon, France “Natural history of autosomal dominant hypercholesterolemia caused by gain-of-function mutations in proprotein convertase subtilisin/kexin type 9 (PCSK9) (funded by Regeneron/Sanofi)”.Applicant
McKenney et al. (2013) Abstract 81st European Atherosclerosis Society (EAS) Congress, Jun. 2-5, 2013, Lyon, France “Dynamics between the monoclonal antibody SAR236553/REGN727, proprotein convertase subtilisin/kexin type 9 and low-density lipoprotein cholesterol (LDL-C) levels (funding: Regeneron/Sanofi)”.Applicant
Reyes-Soffer et al. (2017) Circulation 135:352-362 “Effects of PCSK9 Inhibition with Alirocumab on Lipoprotein Metabolism in Healthy Humans”.Applicant
Lalanne, Florent, et al., “Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells,” Journal of Lipid Research, vol. 46, 2005, pp. 1312-1319.Applicant
Fasano (2009) Atherosclerosis 203:166-171 “Degradation of LDLR Protein Mediated by ‘Gain of Function’ PCSK9 Mutants in Normal and ARH Cells”.Applicant
Voet, et al., “Fundamentals of Biochemistry,” Von Hoffmann Press, Inc., 1999, pp. 260-264.Applicant
Bendig, Mary M., “Humanization of Rodent Monoclonal Antibodies by CDR Grafting,” Methods: A Companion to Methods in Enzymology 8, 83-93 (1995).Applicant
Jefferis, Roy, et al., “Human Immunoglobulin Allotypes,” Review mAbs 1:4, 1-7; Jul./Aug. 2009.Applicant
QSM, “Essential medicines and health products,” WHO Drug Information, vol. 26, No. 2, 2012.Applicant
Voet, et al., “Fundamentals of Biochemistry,” Von Hoffmann Press, Inc., 1999, pp. 80-81.Applicant
Todo, Yasuhiro, et al., “Detailed Analysis of Serum Lipids and Lipoproteins from Japanese Type III Hyperlipoproteinemia with Apolipoprotein E2/2 Phenotype,” Clinica Chimica Acta 348 (2004) 35-40.Applicant
Ason, Brandon, et al., “Improved efficacy for ezetimibe and rosuvastatin by attenuating the induction of PCSK9,” Journal of Lipid Research, vol. 52, 2011, pp. 679-687.Applicant
Chaudhary, Rahul, et al., “PCSK9 inhibitors: A new era of lipid lowering therapy,” World Journal of Cardiology, Feb. 26, 2017; 9(2): 76-91.Applicant
Zimmerman, Marj P., “How Do PCSK9 Inhibitors Stack Up to Statins for Low-Density Lipoprotein Cholesterol Control?”, American health & Drug benefits, Nov. 1, 2015, p. 436.Applicant
Stone, Neil J., et al., “2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults,” A report of the American College of Cardiology/American Heart Association Task for on Practice Guidelines, Journal of the American College of cardiology, vol. 63, No. 25, Nov. 12, 2013 (Nov. 12, 2013), pp. 2889-2934.Applicant
Rahilly-Tierney, Catherine R., “Low-Density Lipoprotein Reduction and Magnitude of Cardiovascular Risk Reduction,” Clinical Study, Preventive Cardiology, Spring 2009, MAVERIC, pp. 80-87.Applicant
McNutt, Markey C., et al., “So Far, PCSK9 Inhibitors Work for All Heterozygous FH Patients,” Circ Cardiovasc Genet.2015;8:749-751.Applicant
Brouwers, M. C. G. J., et al., “Plasma proprotein convertase subtilisin kexin type 9 levels are related to markers of cholesterol synthesis in familial combined hyperlipidemia,” Nutrition, Metabolism & Cardiovascular Diseases (2013) 23, 1115-1121.Applicant
Yamashita, Sizuya, “PCSK9 (proprotein convertase subtilisin/kexin type 9)”, Prevention of Arteriosclerosis, Feb. 10, 2013, vol. 11, No. 4, p. 101-105 (Lambert, Gilles, et al., “Molecular basis of PCSK9 function,” Atherosclerosis 203 (2009) 1-7).Applicant
Ned, R.M., et al., Cascade Screening for Familial Hypercholesterolemia (FH), PLOS Currents Evidence on Genomic Tests, Jul. 1, 2011. Edition 1. doi: 10.1371/currents.RRN1238.Applicant
Notice of Reason(s) for Rejection for JP 2016-516825, dated Jan. 16, 2018.Applicant

US 10,111,953 B2Grant

Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)

Issue Date:2018-10-30

•12 Claims

•13 Drawing Sheets

Abstract

Metadata

Assignee

Regeneron Pharmaceuticals, Inc.

Inventors

Gary Swergold
William J. Sasiela
Robert C. Pordy

Application Information

Application Number:US 14/290,544

Filing Date:2014-05-29

Priority Date:2013-05-30

Art Unit:1644

Classifications

IPC:

A61K39/395C07K16/40A61K31/40A61K39/00

Patent Drawings (13 sheets)

Description

CROSS-REFERENCE TO RELATED APPLICATIONS

FIELD OF THE INVENTION

BACKGROUND

BRIEF SUMMARY OF THE INVENTION

[0010] Other embodiments of the present invention will become apparent from a review of the ensuing detailed description.

BRIEF DESCRIPTION OF THE FIGURES

[0014] FIG. 4 shows mean baseline free PCSK9 levels in non-FH patients receiving atorvastatin or diet alone (no statin).

[0015] FIG. 5 shows LDL-C efficacy curves for patients receiving mAb316P 150 mg SC or placebo±atorvastatin.

[0019] FIG. 13, panels A and B, show the dose response changes in apo CII and apo CIII, respectively, for all doses in Study A (as summarized in Table 1 herein).

DETAILED DESCRIPTION

Methods for Reducing Remnant Cholesterol and Other Lipoprotein Fractions

Patient Population

PCSK9 Inhibitors

[0060] The term “K_D”, as used herein, is intended to refer to the equilibrium dissociation constant of a particular antibody-antigen interaction.

Preparation of Human Antibodies

Pharmaceutical Compositions and Methods of Administration

Dosage

Combination Therapies

Administration Regimens

EXAMPLES

Example 1. Generation of Human Antibodies to Human PCSK9

Example 2: Dynamics Between Anti-PCSK9 Antibody Levels and Low-Density Lipoprotein Cholesterol (LDL-C) Levels

Introduction

[0094] (1) Single-Dose Study:

[0096] (2) Multiple-Dose Study:

[0098] (3) Phase II Study:

Results

Conclusions

Example 3A: An Anti-PCSK9 Antibody Reduces Cholesterol Concentrations of Serum Remnant Lipoprotein Fractions, Very Low Density Lipoproteins, Triglycerides, and Lipoprotein(a) [Lp(a)]

Introduction

[0110]

TABLE 1

Summary of Designs and Dosing for mAb316P Clinical Trials


	Study
	A	B	C

Duration	12 weeks	8 weeks	12 weeks
Patients	hypercholesterolemia	hypercholesterolemia	heterozygous familial
	(n = 183)	(n = 92)	hypercholesterolemeia
			(n = 77)
mAb316P Doses	200-300 mg Q4W	150 mg Q2W + ATV 10	150, 200, 300 mg Q4W
	50-100 mg Q2W	to 80 mg	150 mg Q2W
	150 mg Q2W	150 mg Q2W + ATV 10	(n = 16)
	(n = 31)	to 80 mg (total n = 61)
Placebo	n = 31	Placebo + ATV 10	n = 15
		to 80 mg (n = 31)
Pooled Analysis Population	mAb316P 150 mg Q2W (n = 108)	Placebo (n = 77)

[0111] In Study B, all patients received atorvastatin (ATV) 10 mg prior to randomization, which was uptitrated to ATV 80 mg at the start of randomized treatment in the placebo and one mAb316P arm.

Results/Conclusions

[0115] In the 3 studies, reductions in TG, VLDL-C, and in the cholesterol content of remnant lipoprotein were observed with mAb316P vs. placebo. Results are summarized in Table 2 and FIGS. 7-9.

[0116]

TABLE 2

	Baseline (mg/dL)	Endpoint (mg/dL)	Percent Change	p-value (s)

VLDL	23.24 to 26.31	16.62 to 18.12	−22.33 to −27.95	0.0023 to <0.0001
VLDL₁₊₂-C	9.79 to 10.59	6.59 to 7.31	−21.87 to −31.45	0.0178 to <0.0001
VLDL₃	13.55 to 15.62	10.03 to 10.88	−21.9 to −26.66	0.0011 to <0.0001
TG	135.72 to 157.19	99.9 to 124.44	−13.07 to −21.19	0.6945 to 0.0003
IDL	15.38 to 22.06	6.79 to 8.62	−50.28 to −55.75	<0.0001
RLPC	29.34 to 37.69	16.86 to 19.5	−37.05 to −44.04	<0.0001

[0119]

TABLE 3

Baseline Lp(a) Levels in Patients Included in the Pooled Analysis
	Placebo	mAb316P 150 mg Q2W
	(n = 74)	(n = 102)

Lp(a) values in mg/dL
Overall Population, median	19.0 (6.0-77.0)	29.5 (8.0-70.0)
(IQR)
Range	1.5-299.0	1.5-181.0
Number of Patients Subdivided by Baseline Lp(a)
≤50 mg/dL, n (%)	49 (66.2)	68 (66.7)
>50 mg/dL, n (%)	25 (33.8)	36 (35.3)

*Patients from the mITT population with Lp(a) data available at baseline and end of treatment (Week 8/12 on-treatment value or the last available on-treatment value carried forward).

[0121] Absolute and percentage median reductions from baseline in Lp(a) are summarized in Table 4.

[0122]

TABLE 4

Lp(a) Change From Baseline
		Patients Subdivided by Baseline Lp(a)
All Patients	≤50 mg/dL	>50 mg/dL
pooled	pooled	pooled	pooled	pooled	pooled
placebo	mAb316P	placebo	mAb316P	placebo	mAb316P
treated	treated	treated	treated	treated	treated
(n = 74)	(n = 102)	(n = 49)	(n = 68)	(n = 25)	(n = 34)

Median Lp(a) Change From Baseline, mg/dL (IQR; LOCF)
−0.5	−9.0	0.0	−3.5	−5.0	−26.5
(−5.0-2.0)	(−19.0-−2.0)*	(−3.0-1.5)	(−11.5-−1.5)*	(−11.0-6.0)	(−39.0-−16.0)*
Median Lp(a) Percent Change From Baseline, (IQR; LOCF)
−0.3%	−30.3%	0.0%	−36.1%	−4.4%	−27.0%
(−16.7-11.5)	(−50.0-−19.4)*	(−16.7-16.7)	(−51.1-−17.4)*	(−9.4-7.1)	(−32.6-−19.6)*

*P < 0.0001 vs placebo.

Example 3B: An Anti-PCSK9 Antibody Reduces Apolipoprotein CII and CIII Levels in Serum

Introduction

Results

[0130]

TABLE 5

		P-value		P-value
	Apo CII	versus	Apo CIII	versus
	% change	placebo	% change	placebo

Study A
Placebo	12.0		3.76
	(33.0)		(−5.5 to 27.6)
mAb316P	−21.4	<0.00001	−24.7	<0.00001
150 mg	(26.5)		(−28.4 to −2.9)
Q2W
Study B
Placebo	−10.6		−7.0
	(30.2)		(29.8 to 7.3)
mAb316P	−10.0	0.98	−4.9	0.4426
150 mg Q2W +	(22.7)		(−24.4 to 1.0)
atorvastatin
10 mg
mAb316P	−29.3	0.0067	−22.9	0.0165
150 mg Q2W +	(19.29)		(−28 to −14.0)
atorvastatin
80 mg
Study C
Placebo	1.6		−3.3
	(15.5)		(−15.3 to 5.6)
mAb316P	−9.4	0.0794	−20.2	0.019
150 mg	(28.1)		(−29.0 to 2.5)
Q2W

Conclusions

Example 4: An Anti-PCSK9 Antibody Reduces Cholesterol Concentrations of all Serum Low-Density Lipoprotein Fractions

Introduction

Results/Conclusions

[0137]

TABLE 6

	Baseline (mg/dL)	Endpoint (mg/dL)	Percent Change	p-value

LDL₁	16.18 to 25.92	3.56 to 6.81	−68.87 to −77.84	<0.0001
LDL₂	20.29 to 31.46	3.04 to 7.84	−77.85 to −84.17	<0.0001
LDL₃₄	46.33 to 49.16	14.9 to 22.29	−48.77 to −68.49	<0.0001

Example 5: Effects of an Anti-PCSK9 Antibody on Lipoprotein Particle Concentrations

Background

[0143] The present Example sets forth an evaluation of the effects of mAb316P on the concentration and size of lipoprotein particles.

Methods

[0145] Diameter range estimates for the subclasses were as follows:

[0146] VLDL-P: small VLDL-P=29 to 42 nm; medium VLDL-P=42 to 60 nm; large VLDL-P>60 nm;

[0147] LDL-P: small LDL-P=18 to 20.5 nm; large LDL-P=20.5 to 23 nm; intermediate-density lipoprotein particles (IDL-P)=23 to 29 nm;

[0148] HDL-P: small HDL-P=7.3 to 8.2 nm; medium HDL-P=8.2 to 9.4 nm; and large HDL-P=9.4 to 14 nm.

Results

[0151] Table 7 shows lipoprotein particle concentrations before and after mAb316P 150 mg SC Q2W compared to placebo.

[0152]

TABLE 7

Lipoprotein particle concentrations (nmol/L) for
placebo (n = 31) and mAb316P 150 mg Q2W (n = 28).
Mean (sd) or median (Q1:Q3)
[proportion of total]	Baseline	Week 12	% change

		PLACEBO
LDL	Total LDL	1422.5	(321.3)	1383.8	(327.9)	−1.0%
	Intermediate	110	(51:166.5)	57	(24.5:144.5)	−15.0%
	density
	lipoprotein
	Large LDL	546.6	(205.3)	431.8	(217.4)	−21.8%
	Small LDL	755.3	(304.9)	847.6	(375.1)	17.8%
VLDL +	Total VLDL +	61.9	(47.8:95.6)	83.9	(45:102.2)	33.4%
chylomicron	chylomicron
	Large VLDL +	3.5	(2.1:8.5)	4.3	(1.8:9.4)	14.3%
	chylomicron
	Medium VLDL	19.3	(13.1:33.9)	33.1	(13.1:51.9)	24.0%
	Small VLDL	35.3	(28.2:47.8)	37.3	(23.4:56.3)	21.4%
HDL	Total HDL	32.9	(6.4)	33.2	(7.4)	1.4%
	Large HDL	3.8	(2.0)	3.9	(2.2)	6.99%
	Medium HDL	9.2	(5.9:14.4)	8	(5.4:10.2)	−13.9%
	Small HDL	18.8	(5.3)	21.3	(5.8)	18.4%
		mAb316P 150 mg Q2W
LDL	Total LDL	1320	(304.0)	475.4	(167.3)†	−63.3%†
	Intermediate	84.5	(33:115)	37	(12:66)*	−52.8%
	density
	lipoprotein
	Large LDL	532.2	(212.9)	152.4	(107.6)†	−71.3%
	Small LDL	666.5	(333.8)	279.9	(191.0)†	−54.0%
VLDL +	Total VLDL +	71.5	(36.9:94.1)	42.0	(30.5:54.1)†	−36.4%†
chylomicron	chylomicron
	Large VLDL +	3.6	(1.8:8.5)	3.1	(1.7:6.9)	5.37%
	chylomicron
	Medium VLDL	18.3	(10.7:50)	14.4	(8.2:26.9)†	−38.92%
	Small VLDL	35.7	(25:49.5)	21.4	(19.9:26.7)*	−33.4%
HDL	Total HDL	32.6	(6.3)	36.1	(6.5)*	11.2%*
	Large HDL	4.8	(3.1)	6.1	(3.5)*	44.6%
	Medium HDL	7.8	(5.6:10.7)	9.8	(6.6:11.3)	17.65%
	Small HDL	19.4	(4.1)	20.0	(5.7)*	2.8%

*P < 0.05;
†P < 0.001 vs. placebo

Conclusion

[0154] mAb316P significantly reduced LDL-P and other lipoprotein particles in a manner similar to its previously reported effect on LDL-C and apolipoprotein B.

Example 6: Effects of an Anti-PCSK9 Antibody on Lipoprotein Subfractions as Determined by Ion Mobility

Background

Methods

Results

[0157] Changes in lipoprotein subfractions and lipid parameters from baseline to Week 12 are set forth in Tables 8A (placebo-treated) and 8B (mAb316P-treated).

[0158]

TABLE 8A

Placebo
			Percent
	Baseline	Week 12	Change

Lipoprotein
subfractions
VLDL + IDL +	1648.44	(453.5)	1728.88	(434.58)	8.25
Total LDL
VLDL (large +	134.97	(109.01 to 152.85)	140.48	(106.18 to 193.49)	6.64
intermediate +
small)
IDL (IDL 1 + 2)	314.28	(282.74 to 407.95)	303.35	(277.99 to 376.17)	−3.3
Total LDL	1172.99	(362.85)	1233.76	(331.13)	8.8
Large LDL	448.23	(173.52)	419.36	(160.98)	−0.26
(LDL 1 + 2a)
Medium LDL	233.2	(105.34)	228.92	(88.12)	5.07
(LDL 2b)
Small LDL	195.17	(85.53)	225.98	(105.1)	24.39
(LDL 3a)
Very Small LDL	296.4	(91.75)	359.49	(136.92)	24.61
(LDL 4a + 4b +
4c + 3b)
HDL (HDL 2b;	23532.48	(5392.57)	24400.97	(5798.21)	0.06
HDL3 + 2a)
Lipid parameters
LDL-C, mg/dL	130.2	(27.3)	120.5	(27.0)	−5.1
HDL-C, mg/dL	49.0	(10.3)	48.9	(13.2)	−1.0
TG, mg/dL	124.0	(92.0 to 187.5)	127.0	(98.0 to 197.0)	9.7
Apo-B, mg/dL	108.3	(19.3)	109.2	(27.0)	2.2
Apo-A1, g/L	1.4	(1.3 to 1.6)	1.4	(1.3 to 1.7)	0.0
Lp(a), g/L	0.2	(0.1 to 0.9)	0.2	(0.07 to 0.85)	0.0

[0159]

TABLE 8B

mAb316P 150 mg Q2W
			Percent
			Change
	Baseline	Week 12	(p-value)

Lipoprotein subfractions
VLDL + IDL + Total LDL	1542.82	(435.5)	767.78	(212.39)	−48.68
			(<0.0001)
VLDL (large +	138.17	(96.41 to 167.8)	77.2	(51.81 to 95.8)	−51.37
intermediate + small)			(<0.0001)
IDL (IDL 1 + 2)	309.64	(268.32 to 363.95)	155.19	(134.05 to 194.5)	−52.29
			(<0.0001)
Total LDL	1078.28	(347.61)	529.35	(171)	−49.84
			(<0.0001)
Large LDL (LDL 1 + 2a)	421.08	(130.03)	152.66	(53.4)	−62.66
			(<0.0001)
Medium LDL (LDL 2b)	200.86	(91.4)	78.67	(40.76)	−58.69
			(<0.0001)
Small LDL (LDL 3a)	172.02	(104.89)	79.24	(38.36)	−48.56
			(<0.0001)
Very Small LDL (LDL	284.31	(101.87)	218.77	(55.66)	−17.91
4a + 4b + 4c + 3b)			(<0.0001)
HDL (HDL 2b;	23480.25	(5281.63)	21888.87	(4515.15)	−0.05
HDL3 + 2a)			(0.0339)
Lipid parameters
LDL-C, mg/dL	123.9	(26.7)	34.2	(15.6)	−72.4
			(<0.0001)*
HDL-C, mg/dL	53.3	(16.1)	55.1	(14.8)	5.5
					(0.570)‡
TG, mg/dL	140.5	(92.5 to 177.5)	99.0	(79.0 to 139.0)	−18.9
			(0.0006)‡
Apo-B, mg/dL	101.6	(26.6)	44.1	(14.1)	−56.1
			(<0.0001)‡
Apo-A1, g/L	1.5	(1.3 to 1.7)	1.6	(1.4 to 1.7)	1.4
			(0.1524)‡
Lp(a), g/L	0.3	(0.1 to 0.6)	0.1	(0.05 to 0.41)	−28.6
			(<0.0001)‡

*Statistically significant p-value according to the hierarchical procedure.
‡P-values are not adjusted for multiplicity and are for descriptive purposes only.